



Local.
Reliable.
Accessible.

HealthTeam Advantage Diabetes & Heart Care Plan (HMO CSNP) 2021 Formulary (List of Covered Drugs)

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

Formulary ID: 21526, Version Number: 6

This formulary was updated on 01/24/2021. For more recent information or other questions, please contact us, HealthTeam Advantage Diabetes & Heart Care Plan Healthcare Concierge, at 833-324-3242 or, for TTY users, 711, October 1 - March 31, 8 a.m. to 8 p.m. ET, seven days a week, or April 1 - September 30, 8 a.m. to 8 p.m. ET, Monday through Friday, or visit [HealthTeamAdvantage.com](https://www.healthteamadvantage.com).

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to “we,” “us”, or “our,” it means HealthTeam Advantage. When it refers to “plan” or “our plan,” it means 2021 HealthTeam Advantage Diabetes & Heart Care Plan (HMO CSNP).

This document includes list of the drugs (formulary) for our plan which is current as of 02/01/2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.

What is the HealthTeam Advantage Diabetes & Heart Care Plan Formulary?

A formulary is a list of covered drugs selected by HealthTeam Advantage Diabetes & Heart Care Plan in consultation with a team of healthcare providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. HealthTeam Advantage Diabetes & Heart Care Plan will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a HealthTeam Advantage Diabetes & Heart Care Plan network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

For a complete listing of all prescription drugs covered by HealthTeam Advantage Diabetes & Heart Care Plan, please visit our website or call us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

Can the Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but HealthTeam Advantage Diabetes & Heart Care Plan may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.

- If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the HealthTeam Advantage Diabetes & Heart Care Plan Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary; or add new restrictions to the brand name drug or move it to a different cost sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, [or] add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.
 - If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the HealthTeam Advantage Diabetes & Heart Care Plan Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2021 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2021 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of 02/01/2021. To get updated information about the drugs covered by HealthTeam Advantage Diabetes & Heart Care Plan, please contact us. Our contact information appears on the front and back cover pages. In addition, each month the plan posts an updated Comprehensive formulary and a Formulary Addendum that has all the changes on the website.

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 1. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, Cardiovascular Agents. If you know what your drug is used for, look for the category name in the list that begins on page 2. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 91. The Index provides an alphabetical list of all the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

HealthTeam Advantage Diabetes & Heart Care Plan covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** HealthTeam Advantage Diabetes & Heart Care Plan requires you [or your physician] to get prior authorization for certain drugs. This means that you will need to get approval from HealthTeam Advantage Diabetes & Heart Care Plan before you fill your prescriptions. If you don't get approval, HealthTeam Advantage Diabetes & Heart Care Plan may not cover the drug.
- **Quantity Limits:** For certain drugs, HealthTeam Advantage Diabetes & Heart Care Plan limits the amount of the drug that HealthTeam Advantage Diabetes & Heart Care Plan will cover. For example, HealthTeam Advantage Diabetes & Heart Care Plan provides 30 tablets per prescription for Januvia. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, HealthTeam Advantage Diabetes & Heart Care Plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, HealthTeam Advantage Diabetes & Heart Care Plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, HealthTeam Advantage Diabetes & Heart Care Plan will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 1. You can also get more information about the restrictions applied to specific covered drugs by visiting our Web site. We have posted online a document that explains our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask HealthTeam Advantage Diabetes & Heart Care Plan to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, “How do I request an exception to the HealthTeam Advantage Diabetes & Heart Care Plan formulary?” below for information about how to request an exception.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered.

If you learn that HealthTeam Advantage Diabetes & Heart Care Plan does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by HealthTeam Advantage Diabetes & Heart Care Plan. When you receive the list, show it to your doctor and ask him or her to prescribe a similar drug that is covered by HealthTeam Advantage Diabetes & Heart Care Plan.
- You can ask HealthTeam Advantage Diabetes & Heart Care Plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the HealthTeam Advantage Diabetes & Heart Care Plan Formulary?

You can ask HealthTeam Advantage Diabetes & Heart Care Plan to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at a lower cost-sharing level [if this drug is not on the specialty tier]. If approved this would lower the amount you must pay for your drug.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, HealthTeam Advantage Diabetes & Heart Care Plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, HealthTeam Advantage Diabetes & Heart Care Plan will only approve your request for an exception if the alternative drugs included on the plan’s formulary, the lower cost-sharing drug or

additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, tier, or utilization restriction exception. **When you request a formulary, tier, or utilization restriction exception you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. After your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

In addition, if you experience a change in your treatment setting due to the level of care you require, we will allow an emergency transition or level of care fill. Such transitions include:

- If you are discharged from a hospital or skilled nursing facility to a home setting
- If you are admitted to a hospital or skilled nursing facility from a home setting
- If you transfer from one skilled nursing facility to another and that new facility is serviced by a different pharmacy
- If you end your skilled nursing facility Medicare Part A stay – where payments include all pharmacy charges – and now you need to use your Part D plan benefit
- If you give up Hospice status and revert back to standard Medicare Part A and B coverage

For more information

For more detailed information about your HealthTeam Advantage Diabetes & Heart Care Plan prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about HealthTeam Advantage Diabetes & Heart Care Plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or visit <http://www.medicare.gov>.

HealthTeam Advantage Diabetes & Heart Care Plan's Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by HealthTeam Advantage Diabetes & Heart Care Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 91.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., JANUVIA) and generic drugs are listed in lower-case italics (e.g., *atorvastatin*).

The information in the Requirements/Limits column tells you if HealthTeam Advantage Diabetes & Heart Care Plan has any special requirements for coverage of your drug.

Every drug on HealthTeam Advantage Diabetes & Heart Care Plan's Drug List is in one of six cost-sharing tiers. The second column of the Drug List contains the tier for each drug.

- **Tier 1 – Preferred Generics:** Generic drugs that are available at the lowest cost-share for this plan.
- **Tier 2 – Generics:** Generics that are available at a higher cost to you than drugs in Tier 1.
- **Tier 3 – Preferred Brands:** Generic or brand drugs that are available at a lower cost to you than drugs in Tier 4.
- **Tier 4 – Non-Preferred Drugs:** Generic or brand drugs that are available at a higher cost to you than drugs that are in Tier 3.
- **Tier 5 – Specialty Drugs:** This is the highest cost tier. Includes some injectables and other high-cost drugs.
- **Tier 6 – Select Care Drugs:** Generic or brand drugs that provide the best value for treatment or prevention of many conditions. There is no copay for this tier in the Initial Coverage Stage. In addition, this plan offers additional gap coverage for generics and select insulins. During the Coverage Gap Stage, your out-of-pocket for generics and select insulins will be \$0.

LEGEND

1: Tier 1 - Preferred Generics

2: Tier 2 - Generics

3: Tier 3 - Preferred Brands

4: Tier 4 - Non-Preferred Drugs

5: Tier 5 - Specialty

6: Tier 6 - Select Care

BD: Part B vs Part D - This prescription drug may be covered under Medicare Part B or D depending upon the circumstances.

GC: Gap Coverage. We provide additional coverage of this prescription drug in the coverage gap. Please refer to our Evidence of Coverage for more information about this coverage.

HR: High Risk Medication. These drugs require prior authorization if you are 65 years of age or older. According to medical experts, these drugs may cause more side effects if you are 65 years of age or older. If you are taking one of these drugs, ask your doctor if there are safer options available. If your doctor feels this high risk drug is right for you, you (or your physician) are required to get prior authorization before you fill your prescription for this drug.

LA: Limited Access - This prescription drug is limited to certain pharmacies.

NMO: Not available through Mail Order.

PA: Prior Authorization. You (or your physician) are required to get prior authorization before you fill your prescription for this drug. Without prior approval, we may not cover this drug. If the abbreviation “HR” is also listed, this prior authorization requirement may not apply to you. See the “HR” abbreviation definition located on this page for further details.

QL: Quantity Limit - There is a limit on the amount of this drug that is covered per prescription, or within a specific time frame.

SSM: Senior Savings Model program is offered for this medication at a \$0 copay for a 30-90 days' supply. Please refer to our Evidence of Coverage for more information about this program.

ST: Step Therapy - In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition.

HealthTeam Advantage (List of Covered Drugs)

| Drug Name | Tier | Requirements/Limits |
|--|------|----------------------------------|
| ANALGESICS | | |
| ANALGESICS | | |
| <i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i> | 4 | NMO; QL (180 EA per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i> | 4 | NMO; QL (180 EA per 30 days) |
| NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | 3 | |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | |
| <i>diclofenac sodium er oral tablet extended release 24 hour 100 mg</i> | 1 | GC |
| <i>diclofenac sodium external gel 1 %</i> | 2 | NMO |
| <i>diclofenac sodium external gel 3 %</i> | 4 | PA; NMO; QL (100 GM per 30 days) |
| <i>diclofenac sodium external solution 1.5 %</i> | 4 | NMO |
| <i>diclofenac sodium oral tablet delayed release 25 mg, 50 mg, 75 mg</i> | 1 | GC |
| <i>diclofenac sodium transdermal gel 1 %</i> | 2 | NMO |
| <i>diclofenac-misoprostol oral tablet delayed release 50-0.2 mg, 75-0.2 mg</i> | 3 | |
| <i>diflunisal oral tablet 500 mg</i> | 2 | |
| <i>etodolac er oral tablet extended release 24 hour 400 mg, 500 mg, 600 mg</i> | 4 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 2 | |
| <i>flurbiprofen oral tablet 100 mg</i> | 2 | |
| IBU ORAL TABLET 600 MG, 800 MG | 1 | GC |
| <i>ibuprofen oral suspension 100 mg/5ml</i> | 3 | NMO |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | GC |
| <i>indomethacin er oral capsule extended release 75 mg</i> | 4 | |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | 1 | GC |
| <i>ketoprofen oral capsule 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | GC |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 1 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------------|
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 1 | GC |
| <i>naproxen oral tablet delayed release 375 mg, 500 mg</i> | 1 | GC |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i> | 2 | |
| <i>oxaprozin oral tablet 600 mg</i> | 2 | |
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | 3 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 1 | GC |
| OPIOID ANALGESICS, LONG-ACTING | | |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 3 | NMO; QL (10 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 37.5 mcg/hr, 62.5 mcg/hr, 87.5 mcg/hr</i> | 4 | NMO; QL (10 EA per 30 days) |
| <i>methadone hcl oral solution 10 mg/5ml</i> | 3 | NMO; QL (1800 ML per 30 days) |
| <i>methadone hcl oral solution 5 mg/5ml</i> | 3 | NMO; QL (3600 ML per 30 days) |
| <i>methadone hcl oral tablet 10 mg, 5 mg</i> | 2 | NMO; QL (240 EA per 30 days) |
| <i>morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | 3 | NMO; QL (90 EA per 30 days) |
| <i>oxycodone hcl er oral tablet er 12 hour abuse-deterrent 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</i> | 4 | NMO; QL (60 EA per 30 days) |
| OPIOID ANALGESICS, SHORT-ACTING | | |
| <i>acetaminophen-codeine #3 oral tablet 300-30 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>acetaminophen-codeine oral solution 120-12 mg/5ml</i> | 2 | NMO; QL (5000 ML per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-60 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>butorphanol tartrate nasal solution 10 mg/ml</i> | 2 | NMO |
| <i>codeine sulfate oral tablet 15 mg, 30 mg, 60 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1200 mcg, 1600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 5 | PA; NMO; QL (120 EA per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15ml</i> | 2 | NMO; QL (5500 ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | 2 | NMO; QL (360 EA per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i> | 2 | NMO; QL (150 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------------|
| <i>hydromorphone hcl oral liquid 1 mg/ml</i> | 4 | NMO; QL (1920 ML per 30 days) |
| <i>hydromorphone hcl oral tablet 2 mg, 4 mg</i> | 2 | NMO; QL (360 EA per 30 days) |
| <i>hydromorphone hcl oral tablet 8 mg</i> | 2 | NMO; QL (240 EA per 30 days) |
| <i>morphine sulfate (concentrate) oral solution 100 mg/5ml</i> | 2 | NMO; QL (600 ML per 30 days) |
| <i>morphine sulfate oral solution 10 mg/5ml</i> | 2 | NMO; QL (3600 ML per 30 days) |
| <i>morphine sulfate oral solution 20 mg/5ml</i> | 2 | NMO; QL (2700 ML per 30 days) |
| <i>morphine sulfate oral tablet 15 mg, 30 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>oxycodone hcl oral concentrate 100 mg/5ml</i> | 4 | NMO; QL (360 ML per 30 days) |
| <i>oxycodone hcl oral solution 5 mg/5ml</i> | 4 | NMO; QL (1080 ML per 30 days) |
| <i>oxycodone hcl oral tablet 10 mg, 15 mg, 5 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>oxycodone hcl oral tablet 20 mg, 30 mg</i> | 3 | NMO; QL (180 EA per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> | 4 | NMO; QL (180 EA per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i> | 4 | NMO; QL (360 EA per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i> | 4 | NMO; QL (240 EA per 30 days) |
| <i>oxycodone-aspirin oral tablet 4.8355-325 mg</i> | 4 | NMO; QL (360 EA per 30 days) |
| <i>tramadol hcl oral tablet 100 mg</i> | 1 | NMO; GC; QL (120 EA per 30 days) |
| <i>tramadol hcl oral tablet 50 mg</i> | 1 | NMO; GC; QL (240 EA per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 4 | NMO; QL (360 EA per 30 days) |
| ANESTHETICS | | |
| LOCAL ANESTHETICS | | |
| <i>lidocaine external patch 5 %</i> | 4 | PA; NMO; QL (90 EA per 30 days) |
| <i>lidocaine hcl external solution 4 %</i> | 2 | NMO |
| <i>lidocaine hcl urethral/mucosal external gel 2 %</i> | 2 | NMO; QL (30 ML per 30 days) |
| <i>lidocaine viscous hcl mouth/throat solution 2 %</i> | 2 | NMO |
| <i>lidocaine-prilocaine external cream 2.5-2.5 %</i> | 4 | NMO; QL (30 GM per 30 days) |
| ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS | | |
| ALCOHOL DETERRENTS/ANTI-CRAVING | | |
| <i>acamprosate calcium oral tablet delayed release 333 mg</i> | 2 | |
| <i>disulfiram oral tablet 250 mg</i> | 1 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------------|
| <i>naltrexone hcl oral tablet 50 mg</i> | 1 | NMO; GC |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG | 5 | NMO |
| OPIOID DEPENDENCE | | |
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg</i> | 1 | NMO; GC; QL (90 EA per 30 days) |
| <i>buprenorphine hcl sublingual tablet sublingual 8 mg</i> | 1 | NMO; GC; QL (60 EA per 30 days) |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg</i> | 1 | NMO; GC; QL (360 EA per 30 days) |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 8-2 mg</i> | 1 | NMO; GC; QL (90 EA per 30 days) |
| SUBOXONE SUBLINGUAL FILM 12-3 MG, 2-0.5 MG, 4-1 MG, 8-2 MG | 3 | NMO |
| OPIOID REVERSAL AGENTS | | |
| <i>naloxone hcl injection solution 0.4 mg/ml</i> | 3 | NMO |
| <i>naloxone hcl injection solution cartridge 0.4 mg/ml</i> | 1 | NMO; GC |
| <i>naloxone hcl injection solution prefilled syringe 2 mg/2ml</i> | 3 | NMO |
| NARCAN NASAL LIQUID 4 MG/0.1ML | 3 | NMO |
| SMOKING CESSATION AGENTS | | |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg</i> | 1 | NMO; GC |
| CHANTIX CONTINUING MONTH PAK ORAL TABLET 1 MG | 3 | NMO |
| CHANTIX ORAL TABLET 0.5 MG, 1 MG | 3 | NMO |
| CHANTIX STARTING MONTH PAK ORAL TABLET 0.5 MG X 11 & 1 MG X 42 | 3 | NMO |
| NICOTROL INHALATION INHALER 10 MG | 4 | NMO |
| ANTIBACTERIALS | | |
| AMINOGLYCOSIDES | | |
| <i>amikacin sulfate injection solution 500 mg/2ml</i> | 4 | NMO |
| ARIKAYCE INHALATION SUSPENSION 590 MG/8.4ML | 4 | PA; NMO |
| <i>gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%, 1-0.9 mg/ml-%, 1.2-0.9 mg/ml-%, 1.6-0.9 mg/ml-%</i> | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>gentamicin sulfate external cream 0.1 %</i> | 2 | NMO |
| <i>gentamicin sulfate external ointment 0.1 %</i> | 2 | NMO |
| <i>gentamicin sulfate injection solution 40 mg/ml</i> | 4 | NMO |
| <i>neomycin sulfate oral tablet 500 mg</i> | 2 | NMO |
| <i>paromomycin sulfate oral capsule 250 mg</i> | 4 | NMO |
| <i>streptomycin sulfate intramuscular solution reconstituted 1 gm</i> | 4 | NMO |
| <i>tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml</i> | 4 | NMO |
| ZEMDRI INTRAVENOUS SOLUTION 500 MG/10ML | 5 | NMO |
| ANTIBACTERIALS, OTHER | | |
| AZACTAM INJECTION SOLUTION RECONSTITUTED 1 GM | 4 | NMO |
| <i>aztreonam injection solution reconstituted 1 gm</i> | 4 | NMO |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> | 1 | NMO; GC |
| <i>clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml</i> | 2 | NMO |
| <i>clindamycin phosphate external swab 1 %</i> | 2 | NMO |
| <i>clindamycin phosphate in d5w intravenous solution 300 mg/50ml, 600 mg/50ml, 900 mg/50ml</i> | 4 | NMO |
| <i>clindamycin phosphate injection solution 300 mg/2ml, 600 mg/4ml, 900 mg/6ml</i> | 4 | NMO |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 2 | NMO |
| <i>colistimethate sodium (cba) injection solution reconstituted 150 mg</i> | 4 | BD; NMO |
| <i>daptomycin intravenous solution reconstituted 350 mg</i> | 4 | NMO |
| <i>daptomycin intravenous solution reconstituted 500 mg</i> | 5 | NMO |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25 MG/ML, 50 MG/ML | 4 | NMO |
| <i>linezolid intravenous solution 600 mg/300ml</i> | 5 | NMO |
| <i>linezolid oral suspension reconstituted 100 mg/5ml</i> | 5 | NMO |
| <i>linezolid oral tablet 600 mg</i> | 4 | NMO |
| <i>methenamine hippurate oral tablet 1 gm</i> | 2 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>metronidazole external cream 0.75 %</i> | 4 | NMO |
| <i>metronidazole external gel 0.75 %, 1 %</i> | 4 | NMO |
| <i>metronidazole external lotion 0.75 %</i> | 4 | NMO |
| <i>metronidazole in nacl intravenous solution 5-0.79 mg/ml-%</i> | 4 | NMO |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 2 | NMO |
| <i>metronidazole vaginal gel 0.75 %</i> | 4 | NMO |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | NMO |
| <i>nitrofurantoin monohyd macro oral capsule 100 mg</i> | 2 | NMO |
| <i>nitrofurantoin oral suspension 25 mg/5ml</i> | 4 | NMO |
| SIVEXTRO INTRAVENOUS SOLUTION RECONSTITUTED 200 MG | 5 | NMO |
| SIVEXTRO ORAL TABLET 200 MG | 5 | NMO |
| <i>tigecycline intravenous solution reconstituted 50 mg</i> | 5 | BD; NMO |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 4 | NMO |
| <i>trimethoprim oral tablet 100 mg</i> | 1 | NMO; GC |
| <i>vancomycin hcl intravenous solution reconstituted 1 gm, 10 gm, 250 mg, 500 mg, 750 mg</i> | 4 | NMO |
| <i>vancomycin hcl oral capsule 125 mg</i> | 4 | NMO |
| <i>vancomycin hcl oral capsule 250 mg</i> | 5 | NMO |
| XIFAXAN ORAL TABLET 200 MG, 550 MG | 5 | NMO |
| BETA-LACTAM, CEPHALOSPORINS | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 2 | NMO |
| <i>cefaclor oral suspension reconstituted 125 mg/5ml, 250 mg/5ml, 375 mg/5ml</i> | 4 | NMO |
| <i>cefadroxil oral capsule 500 mg</i> | 2 | NMO |
| <i>cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml</i> | 2 | NMO |
| <i>cefadroxil oral tablet 1 gm</i> | 2 | NMO |
| <i>cefazolin sodium injection solution reconstituted 1 gm, 10 gm, 500 mg</i> | 4 | NMO |
| <i>cefdinir oral capsule 300 mg</i> | 2 | NMO |
| <i>cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 3 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>cefepime hcl injection solution reconstituted 1 gm, 2 gm</i> | 4 | NMO |
| <i>cefixime oral capsule 400 mg</i> | 4 | NMO |
| <i>cefotetan disodium injection solution reconstituted 1 gm, 2 gm</i> | 4 | NMO |
| <i>cefoxitin sodium injection solution reconstituted 10 gm</i> | 4 | NMO |
| <i>cefoxitin sodium intravenous solution reconstituted 1 gm, 2 gm</i> | 4 | NMO |
| <i>cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml</i> | 4 | NMO |
| <i>cefpodoxime proxetil oral tablet 100 mg, 200 mg</i> | 4 | NMO |
| <i>cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 3 | NMO |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | NMO |
| <i>ceftazidime injection solution reconstituted 1 gm, 2 gm, 6 gm</i> | 4 | NMO |
| <i>ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg</i> | 4 | NMO |
| <i>ceftriaxone sodium intravenous solution reconstituted 10 gm</i> | 4 | NMO |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | NMO |
| <i>cefuroxime sodium injection solution reconstituted 7.5 gm, 750 mg</i> | 4 | NMO |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5 gm</i> | 4 | NMO |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | NMO; GC |
| <i>cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | NMO |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400 MG, 600 MG | 4 | NMO |
| ZERBAXA INTRAVENOUS SOLUTION RECONSTITUTED 1.5 (1-0.5) GM | 5 | NMO |
| BETA-LACTAM, PENICILLINS | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | NMO; GC |
| <i>amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml</i> | 1 | NMO; GC |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | NMO; GC |
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i> | 1 | NMO; GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>amoxicillin-pot clavulanate er oral tablet extended release 12 hour 1000-62.5 mg</i> | 4 | NMO |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml</i> | 2 | NMO |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 2 | NMO |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg</i> | 2 | NMO |
| <i>ampicillin oral capsule 500 mg</i> | 1 | NMO; GC |
| <i>ampicillin sodium injection solution reconstituted 1 gm, 125 mg</i> | 4 | NMO |
| <i>ampicillin sodium intravenous solution reconstituted 10 gm</i> | 4 | NMO |
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 4 | NMO |
| <i>ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm</i> | 4 | NMO |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION 1200000 UNIT/2ML, 2400000 UNIT/4ML, 600000 UNIT/ML | 4 | NMO |
| <i>dicloxacillin sodium oral capsule 250 mg, 500 mg</i> | 2 | NMO |
| <i>nafcillin sodium injection solution reconstituted 1 gm, 2 gm</i> | 4 | NMO |
| <i>nafcillin sodium intravenous solution reconstituted 10 gm</i> | 4 | NMO |
| <i>oxacillin sodium injection solution reconstituted 1 gm, 2 gm</i> | 4 | NMO |
| <i>oxacillin sodium intravenous solution reconstituted 10 gm</i> | 4 | NMO |
| <i>penicillin g pot in dextrose intravenous solution 40000 unit/ml, 60000 unit/ml</i> | 4 | NMO |
| <i>penicillin g potassium injection solution reconstituted 20000000 unit</i> | 4 | NMO |
| <i>penicillin g sodium injection solution reconstituted 5000000 unit</i> | 4 | NMO |
| <i>penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | NMO |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | NMO; GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>piperacillin sod-tazobactam so intravenous solution reconstituted 2.25 (2-0.25) gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm</i> | 4 | NMO |
| CARBAPENEMS | | |
| <i>ertapenem sodium injection solution reconstituted 1 gm</i> | 4 | NMO |
| <i>imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg</i> | 4 | NMO |
| <i>meropenem intravenous solution reconstituted 1 gm, 500 mg</i> | 4 | NMO |
| MACROLIDES | | |
| <i>azithromycin intravenous solution reconstituted 500 mg</i> | 4 | NMO |
| <i>azithromycin oral packet 1 gm</i> | 4 | NMO |
| <i>azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 2 | NMO |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack)</i> | 1 | NMO; GC |
| <i>azithromycin oral tablet 600 mg</i> | 2 | NMO |
| <i>clarithromycin er oral tablet extended release 24 hour 500 mg</i> | 2 | NMO |
| <i>clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 3 | NMO |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | NMO |
| DIFICID ORAL TABLET 200 MG | 5 | NMO |
| ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | 4 | NMO |
| ERYTHROCIN STEARATE ORAL TABLET 250 MG | 4 | NMO |
| <i>erythromycin base oral capsule delayed release particles 250 mg</i> | 4 | NMO |
| <i>erythromycin base oral tablet 250 mg, 500 mg</i> | 4 | NMO |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 400 mg/5ml</i> | 4 | NMO |
| <i>erythromycin ethylsuccinate oral tablet 400 mg</i> | 4 | NMO |
| QUINOLONES | | |
| BESIVANCE OPHTHALMIC SUSPENSION 0.6 % | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>ciprofloxacin hcl ophthalmic solution 0.3 %</i> | 2 | NMO |
| <i>ciprofloxacin hcl oral tablet 100 mg, 250 mg, 500 mg, 750 mg</i> | 1 | NMO; GC |
| <i>ciprofloxacin in d5w intravenous solution 200 mg/100ml</i> | 4 | NMO |
| <i>levofloxacin in d5w intravenous solution 500 mg/100ml, 750 mg/150ml</i> | 4 | NMO |
| <i>levofloxacin intravenous solution 25 mg/ml</i> | 4 | NMO |
| <i>levofloxacin oral solution 25 mg/ml</i> | 4 | NMO |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | NMO; GC |
| <i>moxifloxacin hcl in nacl intravenous solution 400 mg/250ml</i> | 4 | NMO |
| <i>moxifloxacin hcl oral tablet 400 mg</i> | 4 | NMO |
| SULFONAMIDES | | |
| <i>sulfacetamide sodium (acne) external lotion 10 %</i> | 2 | NMO |
| <i>sulfadiazine oral tablet 500 mg</i> | 4 | NMO |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i> | 2 | NMO |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1 | NMO; GC |
| TETRACYCLINES | | |
| DOXY 100 INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 4 | NMO |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 2 | NMO |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 2 | NMO |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | 4 | NMO |
| <i>doxycycline monohydrate oral suspension reconstituted 25 mg/5ml</i> | 3 | NMO |
| <i>doxycycline monohydrate oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | 4 | NMO |
| <i>minocycline hcl er oral tablet extended release 24 hour 105 mg, 80 mg</i> | 4 | NMO |
| <i>minocycline hcl oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | NMO |
| <i>minocycline hcl oral tablet 100 mg, 50 mg, 75 mg</i> | 4 | NMO |
| ANTICONVULSANTS | | |
| ANTICONVULSANTS, OTHER | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| BRIVIACT ORAL SOLUTION 10 MG/ML | 4 | |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 4 | |
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG | 4 | PA |
| DIACOMIT ORAL PACKET 250 MG, 500 MG | 4 | PA |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 4 | PA |
| <i>felbamate oral suspension 600 mg/5ml</i> | 5 | NMO |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | 4 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 4 | PA |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 4 | |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 4 | |
| <i>lamotrigine er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 4 | |
| <i>lamotrigine oral kit 25 & 50 & 100 mg</i> | 4 | NMO |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | GC |
| <i>lamotrigine oral tablet chewable 25 mg, 5 mg</i> | 2 | |
| <i>lamotrigine oral tablet dispersible 100 mg, 50 mg</i> | 4 | |
| <i>lamotrigine oral tablet dispersible 200 mg, 25 mg</i> | 2 | |
| <i>lamotrigine starter kit-blue oral kit 35 x 25 mg</i> | 4 | NMO |
| <i>lamotrigine starter kit-green oral kit 84 x 25 mg & 14x100 mg</i> | 4 | NMO |
| <i>lamotrigine starter kit-orange oral kit 42 x 25 mg & 7 x 100 mg</i> | 4 | NMO |
| <i>levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg</i> | 3 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | 2 | |
| <i>levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg</i> | 1 | GC |
| <i>phenobarbital oral elixir 20 mg/5ml</i> | 2 | |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 2 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> | 1 | GC |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG, 250 MG, 500 MG, 750 MG | 4 | |
| <i>valproic acid oral capsule 250 mg</i> | 2 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|-----------------------------|
| <i>valproic acid oral solution 250 mg/5ml</i> | 2 | |
| XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 50 & 200 MG | 4 | |
| XCOPRI (350 MG DAILY DOSE) ORAL TABLET THERAPY PACK 150 & 200 MG | 4 | |
| XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 4 | |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG, 14 X 150 MG & 14 X 200 MG, 14 X 50 MG & 14 X 100 MG | 4 | NMO |
| CALCIUM CHANNEL MODIFYING AGENTS | | |
| CELONTIN ORAL CAPSULE 300 MG | 3 | |
| <i>ethosuximide oral capsule 250 mg</i> | 2 | |
| <i>ethosuximide oral solution 250 mg/5ml</i> | 1 | GC |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| GAMMA-AMINO BUTYRIC ACID (GABA) AUGMENTING AGENTS | | |
| <i>clobazam oral suspension 2.5 mg/ml</i> | 4 | QL (480 ML per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | 4 | QL (60 EA per 30 days) |
| DIASTAT ACUDIAL RECTAL GEL 10 MG, 20 MG | 4 | NMO |
| DIASTAT PEDIATRIC RECTAL GEL 2.5 MG | 4 | NMO |
| <i>diazepam rectal gel 10 mg, 2.5 mg, 20 mg</i> | 4 | NMO |
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> | 1 | GC |
| <i>gabapentin oral solution 250 mg/5ml</i> | 2 | |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | 2 | |
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML | 4 | NMO |
| SYMPAZAN ORAL FILM 10 MG, 20 MG | 5 | NMO; QL (60 EA per 30 days) |
| SYMPAZAN ORAL FILM 5 MG | 4 | QL (60 EA per 30 days) |
| <i>tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 4 | |
| VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML | 4 | NMO |
| VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML | 4 | NMO |
| VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML | 4 | NMO |
| <i>vigabatrin oral packet 500 mg</i> | 5 | LA; NMO |
| <i>vigabatrin oral tablet 500 mg</i> | 5 | NMO |
| VIGADRONE ORAL PACKET 500 MG | 5 | NMO |
| SODIUM CHANNEL AGENTS | | |
| APTIOM ORAL TABLET 200 MG | 4 | |
| APTIOM ORAL TABLET 400 MG, 600 MG, 800 MG | 5 | NMO |
| BANZEL ORAL SUSPENSION 40 MG/ML | 5 | NMO |
| BANZEL ORAL TABLET 200 MG, 400 MG | 5 | NMO |
| <i>carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg</i> | 2 | |
| <i>carbamazepine oral suspension 100 mg/5ml</i> | 2 | |
| <i>carbamazepine oral tablet 200 mg</i> | 2 | |
| <i>carbamazepine oral tablet chewable 100 mg</i> | 1 | GC |
| DILANTIN ORAL CAPSULE 30 MG | 3 | |
| EPITOL ORAL TABLET 200 MG | 2 | |
| <i>oxcarbazepine oral suspension 300 mg/5ml</i> | 3 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg</i> | 1 | GC |
| <i>oxcarbazepine oral tablet 600 mg</i> | 2 | |
| <i>phenytoin oral suspension 125 mg/5ml</i> | 2 | |
| <i>phenytoin oral tablet chewable 50 mg</i> | 1 | GC |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 2 | |
| VIMPAT ORAL SOLUTION 10 MG/ML | 4 | |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 4 | |
| ANTIDEMENTIA AGENTS | | |
| ANTIDEMENTIA AGENTS, OTHER | | |
| <i>memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg</i> | 3 | |
| <i>memantine hcl oral solution 2 mg/ml</i> | 2 | |
| <i>memantine hcl oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>memantine hcl oral tablet 28 x 5 mg & 21 x 10 mg</i> | 2 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|-----------------------------|
| NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG | 3 | NMO |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 3 | |
| CHOLINESTERASE INHIBITORS | | |
| <i>donepezil hcl oral tablet 10 mg, 5 mg</i> | 1 | GC |
| <i>donepezil hcl oral tablet dispersible 10 mg, 5 mg</i> | 2 | |
| <i>galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg</i> | 2 | |
| <i>galantamine hydrobromide oral solution 4 mg/ml</i> | 3 | |
| <i>galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24hr, 4.6 mg/24hr, 9.5 mg/24hr</i> | 2 | QL (30 EA per 30 days) |
| ANTIDEPRESSANTS | | |
| ANTIDEPRESSANTS, OTHER | | |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg, 150 mg, 200 mg</i> | 1 | GC |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg, 300 mg</i> | 1 | GC |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 450 mg</i> | 3 | |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 1 | GC |
| <i>maprotiline hcl oral tablet 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg, 7.5 mg</i> | 1 | GC |
| <i>mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg</i> | 2 | |
| <i>olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg</i> | 4 | |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | 4 | |
| MONOAMINE OXIDASE INHIBITORS | | |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR | 5 | NMO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| MARPLAN ORAL TABLET 10 MG | 4 | |
| <i>phenelzine sulfate oral tablet 15 mg</i> | 2 | |
| <i>tranylcypromine sulfate oral tablet 10 mg</i> | 4 | |
| SSRIS/SNRIS (SELECTIVE SEROTONIN REUPTAKE INHIBITOR/SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR) | | |
| <i>citalopram hydrobromide oral solution 10 mg/5ml</i> | 2 | |
| <i>citalopram hydrobromide oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | GC |
| <i>desvenlafaxine er oral tablet extended release 24 hour 100 mg, 50 mg</i> | 4 | |
| <i>desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | 4 | |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG | 3 | QL (60 EA per 30 days) |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 40 mg, 60 mg</i> | 2 | |
| <i>escitalopram oxalate oral solution 5 mg/5ml</i> | 2 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | GC |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 20 MG, 40 MG, 80 MG | 3 | |
| FETZIMA TITRATION ORAL CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG | 3 | NMO |
| <i>fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | GC |
| <i>fluoxetine hcl oral capsule delayed release 90 mg</i> | 4 | |
| <i>fluoxetine hcl oral solution 20 mg/5ml</i> | 2 | |
| <i>fluoxetine hcl oral tablet 10 mg</i> | 2 | |
| <i>fluoxetine hcl oral tablet 20 mg, 60 mg</i> | 4 | |
| <i>fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg</i> | 3 | |
| <i>nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 4 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>paroxetine hcl er oral tablet extended release 24 hour 12.5 mg, 25 mg, 37.5 mg</i> | 2 | |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | GC |
| PAXIL ORAL SUSPENSION 10 MG/5ML | 4 | |
| <i>sertraline hcl oral concentrate 20 mg/ml</i> | 1 | GC |
| <i>sertraline hcl oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>trazodone hcl oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | GC |
| <i>trazodone hcl oral tablet 300 mg</i> | 2 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 4 | |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg, 75 mg</i> | 1 | GC |
| <i>venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 1 | GC |
| VIIBRYD ORAL TABLET 10 MG, 20 MG, 40 MG | 3 | |
| VIIBRYD STARTER PACK ORAL KIT 10 & 20 MG | 3 | NMO |
| TRICYCLICS | | |
| <i>amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 3 | |
| <i>clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxepin hcl oral concentrate 10 mg/ml</i> | 2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg</i> | 4 | |
| <i>nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 1 | GC |
| <i>nortriptyline hcl oral solution 10 mg/5ml</i> | 2 | |
| <i>protriptyline hcl oral tablet 10 mg, 5 mg</i> | 4 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|-------------------------------------|
| <i>trimipramine maleate oral capsule 100 mg, 25 mg, 50 mg</i> | 4 | |
| ANTIEMETICS | | |
| ANTIEMETICS, OTHER | | |
| COMPRO RECTAL SUPPOSITORY 25 MG | 4 | NMO |
| <i>meclizine hcl oral tablet 12.5 mg, 25 mg</i> | 1 | NMO; GC |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | 1 | GC |
| <i>prochlorperazine rectal suppository 25 mg</i> | 4 | NMO |
| <i>promethazine hcl oral syrup 6.25 mg/5ml</i> | 4 | NMO |
| <i>promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | NMO; GC |
| <i>scopolamine transdermal patch 72 hour 1 mg/3days</i> | 4 | NMO |
| TRANSDERM-SCOP (1.5 MG) TRANSDERMAL PATCH 72 HOUR 1 MG/3DAYS | 4 | NMO |
| <i>trimethobenzamide hcl oral capsule 300 mg</i> | 4 | NMO |
| EMETOGENIC THERAPY ADJUNCTS | | |
| <i>aprepitant oral capsule 125 mg, 40 mg, 80 mg</i> | 4 | BD; NMO; QL (8 EA per 30 days) |
| <i>aprepitant oral capsule 80 & 125 mg</i> | 4 | BD; NMO; QL (12 EA per 30 days) |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | 4 | PA; NMO; QL (60 EA per 30 days) |
| <i>granisetron hcl oral tablet 1 mg</i> | 4 | BD; NMO; QL (60 EA per 30 days) |
| <i>ondansetron hcl oral solution 4 mg/5ml</i> | 2 | BD; NMO; QL (450 ML per 30 days) |
| <i>ondansetron hcl oral tablet 24 mg</i> | 2 | BD; NMO; QL (30 EA per 30 days) |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 1 | BD; NMO; GC; QL (90 EA per 30 days) |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i> | 2 | BD; NMO; QL (90 EA per 30 days) |
| ANTIFUNGALS | | |
| ANTIFUNGALS | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | BD; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG | 5 | BD; NMO |
| <i>amphotericin b intravenous solution reconstituted 50 mg</i> | 4 | BD; NMO |
| <i>caspofungin acetate intravenous solution reconstituted 50 mg, 70 mg</i> | 5 | BD; NMO |
| <i>ciclopirox olamine external cream 0.77 %</i> | 2 | NMO |
| <i>ciclopirox olamine external suspension 0.77 %</i> | 3 | NMO |
| <i>clotrimazole external cream 1 %</i> | 2 | NMO |
| <i>clotrimazole external solution 1 %</i> | 2 | NMO |
| <i>clotrimazole mouth/throat troche 10 mg</i> | 2 | NMO |
| <i>econazole nitrate external cream 1 %</i> | 2 | NMO |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-%</i> | 4 | NMO |
| <i>fluconazole oral suspension reconstituted 10 mg/ml, 40 mg/ml</i> | 2 | NMO |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | NMO |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 5 | NMO |
| <i>griseofulvin microsize oral suspension 125 mg/5ml</i> | 4 | NMO |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 4 | NMO |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 4 | NMO |
| <i>itraconazole oral capsule 100 mg</i> | 4 | PA; NMO |
| <i>itraconazole oral solution 10 mg/ml</i> | 3 | PA; NMO |
| JUBLIA EXTERNAL SOLUTION 10 % | 4 | NMO |
| <i>ketoconazole external cream 2 %</i> | 2 | NMO |
| <i>ketoconazole external shampoo 2 %</i> | 1 | NMO; GC |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | NMO |
| <i>micafungin sodium intravenous solution reconstituted 100 mg, 50 mg</i> | 5 | NMO |
| <i>miconazole 3 vaginal suppository 200 mg</i> | 1 | NMO; GC |
| NOXAFIL ORAL SUSPENSION 40 MG/ML | 5 | NMO |
| NYAMYC EXTERNAL POWDER 100000 UNIT/GM | 2 | NMO |
| <i>nystatin external cream 100000 unit/gm</i> | 2 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------------|
| <i>nystatin external ointment 100000 unit/gm</i> | 2 | NMO |
| <i>nystatin external powder 100000 unit/gm</i> | 2 | NMO |
| <i>nystatin mouth/throat suspension 100000 unit/ml</i> | 1 | NMO; GC |
| <i>nystatin oral tablet 500000 unit</i> | 2 | NMO |
| NYSTOP EXTERNAL POWDER 100000 UNIT/GM | 2 | NMO |
| <i>posaconazole oral tablet delayed release 100 mg</i> | 4 | |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | NMO; GC |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | NMO |
| <i>terconazole vaginal suppository 80 mg</i> | 2 | NMO |
| <i>voriconazole intravenous solution reconstituted 200 mg</i> | 5 | NMO |
| <i>voriconazole oral suspension reconstituted 40 mg/ml</i> | 5 | PA; NMO; QL (300 ML per 30 days) |
| <i>voriconazole oral tablet 200 mg</i> | 5 | PA; NMO; QL (120 EA per 30 days) |
| <i>voriconazole oral tablet 50 mg</i> | 4 | PA; NMO; QL (120 EA per 30 days) |
| ANTIGOUT AGENTS | | |
| ANTIGOUT AGENTS | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | GC |
| <i>colchicine oral tablet 0.6 mg</i> | 2 | NMO |
| <i>colchicine-probenecid oral tablet 0.5-500 mg</i> | 2 | |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 3 | |
| <i>probenecid oral tablet 500 mg</i> | 2 | |
| ANTIMIGRAINE AGENTS | | |
| ERGOT ALKALOIDS | | |
| <i>dihydroergotamine mesylate nasal solution 4 mg/ml</i> | 5 | NMO |
| MIGERGOT RECTAL SUPPOSITORY 2-100 MG | 4 | NMO |
| PROPHYLACTIC | | |
| EMGALITY (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 3 | |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 120 MG/ML | 3 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|------------------------------------|
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML | 3 | |
| <i>propranolol hcl er oral capsule extended release 24 hour 80 mg</i> | 6 | GC |
| <i>propranolol hcl oral tablet 80 mg</i> | 6 | GC |
| <i>topiramate oral capsule sprinkle 15 mg, 25 mg</i> | 2 | |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | GC |
| SEROTONIN (5-HT) RECEPTOR AGONIST | | |
| <i>naratriptan hcl oral tablet 1 mg, 2.5 mg</i> | 3 | NMO; QL (12 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet 10 mg, 5 mg</i> | 2 | NMO; QL (12 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 10 mg, 5 mg</i> | 2 | NMO; QL (12 EA per 30 days) |
| <i>sumatriptan nasal solution 20 mg/act, 5 mg/act</i> | 4 | NMO; QL (18 EA per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | NMO; GC; QL (12 EA per 30 days) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 4 mg/0.5ml, 6 mg/0.5ml</i> | 4 | NMO; QL (10 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5ml</i> | 4 | NMO; QL (8 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml</i> | 4 | NMO; QL (4.5 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 6 mg/0.5ml</i> | 4 | NMO; QL (10 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution prefilled syringe 6 mg/0.5ml</i> | 4 | NMO; QL (8 ML per 30 days) |
| ANTIMYASTHENIC AGENTS | | |
| PARASYMPATHOMIMETICS | | |
| <i>guanidine hcl oral tablet 125 mg</i> | 3 | NMO |
| <i>pyridostigmine bromide oral tablet 30 mg, 60 mg</i> | 2 | NMO |
| ANTIMYCOBACTERIALS | | |
| ANTIMYCOBACTERIALS, OTHER | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | |
| PRIFTIN ORAL TABLET 150 MG | 4 | NMO |
| <i>rifabutin oral capsule 150 mg</i> | 4 | NMO |
| ANTITUBERCULARS | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|--------------------------------------|
| <i>ethambutol hcl oral tablet 100 mg, 400 mg</i> | 2 | NMO |
| <i>isoniazid oral syrup 50 mg/5ml</i> | 2 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | GC |
| PASER ORAL PACKET 4 GM | 4 | NMO |
| <i>pyrazinamide oral tablet 500 mg</i> | 4 | NMO |
| <i>rifampin intravenous solution reconstituted 600 mg</i> | 4 | NMO |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 3 | NMO |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | NMO |
| TRECTOR ORAL TABLET 250 MG | 4 | NMO |
| ANTINEOPLASTICS | | |
| ALKYLATING AGENTS | | |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 4 | BD; NMO |
| LEUKERAN ORAL TABLET 2 MG | 3 | NMO |
| MATULANE ORAL CAPSULE 50 MG | 5 | NMO |
| VALCHLOR EXTERNAL GEL 0.016 % | 5 | NMO |
| ANTIANDROGENS | | |
| <i>abiraterone acetate oral tablet 250 mg</i> | 5 | PA; NMO; QL (120 EA per 30 days) |
| <i>bicalutamide oral tablet 50 mg</i> | 1 | NMO; GC; QL (30 EA per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA; LA; NMO; QL (120 EA per 30 days) |
| <i>flutamide oral capsule 125 mg</i> | 4 | NMO |
| LYSODREN ORAL TABLET 500 MG | 3 | NMO |
| <i>nilutamide oral tablet 150 mg</i> | 5 | NMO; QL (60 EA per 30 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA; LA; NMO; QL (120 EA per 30 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| ZYTIGA ORAL TABLET 500 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| ANTIANGIOGENIC AGENTS | | |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA; LA; NMO |
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG | 5 | PA; LA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|---------------------------------|
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA; NMO |
| ANTIESTROGENS/MODIFIERS | | |
| EMCYT ORAL CAPSULE 140 MG | 3 | NMO |
| SOLTAMOX ORAL SOLUTION 10 MG/5ML | 4 | |
| <i>tamoxifen citrate oral tablet 10 mg, 20 mg</i> | 1 | GC |
| <i>toremifene citrate oral tablet 60 mg</i> | 5 | NMO; QL (30 EA per 30 days) |
| ANTIMETABOLITES | | |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 4 | |
| <i>hydroxyurea oral capsule 500 mg</i> | 1 | NMO; GC |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA; NMO |
| PURIXAN ORAL SUSPENSION 2000 MG/100ML | 5 | NMO |
| TABLOID ORAL TABLET 40 MG | 3 | NMO |
| ANTINEOPLASTICS, OTHER | | |
| IDHIFA ORAL TABLET 100 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| IDHIFA ORAL TABLET 50 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA; NMO |
| KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA; NMO |
| KISQALI FEMARA(200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA; NMO |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 3 | NMO |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG | 5 | PA; NMO |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA; LA; NMO |
| MESNEX ORAL TABLET 400 MG | 5 | NMO |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA; NMO |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5 MG | 5 | NMO |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | BD; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------------|
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; NMO |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; NMO |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; NMO |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; NMO |
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; NMO |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; NMO |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA; NMO |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | NMO; QL (120 EA per 30 days) |
| AROMATASE INHIBITORS, 3RD GENERATION | | |
| <i>anastrozole oral tablet 1 mg</i> | 1 | GC |
| <i>exemestane oral tablet 25 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>letrozole oral tablet 2.5 mg</i> | 1 | GC |
| MOLECULAR TARGET INHIBITORS | | |
| AFINITOR DISPERZ ORAL TABLET SOLUBLE 2 MG, 3 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| AFINITOR DISPERZ ORAL TABLET SOLUBLE 5 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| AFINITOR ORAL TABLET 10 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA; NMO |
| ALUNBRIG ORAL TABLET 180 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA; NMO; QL (180 EA per 30 days) |
| ALUNBRIG ORAL TABLET 90 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA; NMO; QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|--------------------------------------|
| BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG | 5 | PA; NMO |
| BOSULIF ORAL TABLET 100 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA; LA; NMO; QL (180 EA per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG | 5 | PA; NMO |
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA; LA; NMO; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 100 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG | 5 | PA; NMO; QL (90 EA per 30 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA; LA; NMO |
| DAURISMO ORAL TABLET 100 MG, 25 MG | 5 | PA; NMO |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | NMO |
| <i>erlotinib hcl oral tablet 100 mg, 150 mg</i> | 5 | PA; NMO; QL (30 EA per 30 days) |
| <i>erlotinib hcl oral tablet 25 mg</i> | 5 | PA; NMO; QL (90 EA per 30 days) |
| <i>everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 5 | PA; NMO; QL (30 EA per 30 days) |
| FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG | 5 | PA; NMO |
| GAVRETO ORAL CAPSULE 100 MG | 5 | PA; NMO |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|---------------------------------|
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5 | PA; NMO |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA; NMO |
| ICLUSIG ORAL TABLET 15 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| ICLUSIG ORAL TABLET 45 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| <i>imatinib mesylate oral tablet 100 mg</i> | 5 | NMO; QL (180 EA per 30 days) |
| <i>imatinib mesylate oral tablet 400 mg</i> | 5 | NMO; QL (60 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG, 70 MG | 5 | PA; NMO |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG | 5 | PA; NMO |
| INLYTA ORAL TABLET 1 MG | 5 | NMO; QL (180 EA per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | NMO; QL (60 EA per 30 days) |
| INREBIC ORAL CAPSULE 100 MG | 5 | PA; NMO |
| IRESSA ORAL TABLET 250 MG | 5 | PA; NMO |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; NMO |
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; NMO |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; NMO |
| KOSELUGO ORAL CAPSULE 10 MG, 25 MG | 5 | PA; NMO |
| <i>lapatinib ditosylate oral tablet 250 mg</i> | 5 | NMO; QL (150 EA per 30 days) |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG | 5 | PA; NMO |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG | 5 | PA; NMO |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG | 5 | PA; NMO |
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG | 5 | PA; NMO |
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|--------------------------------------|
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG | 5 | PA; NMO |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG | 5 | PA; NMO |
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG | 5 | PA; NMO |
| LORBRENA ORAL TABLET 100 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG, 2 MG | 5 | PA; NMO |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA; LA; NMO; QL (180 EA per 30 days) |
| NERLYNX ORAL TABLET 40 MG | 5 | PA; LA; NMO; QL (180 EA per 30 days) |
| NEXAVAR ORAL TABLET 200 MG | 5 | PA; LA; NMO; QL (120 EA per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA; LA; NMO |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA; NMO |
| PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA; NMO |
| PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG | 5 | PA; NMO |
| PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG | 5 | PA; NMO |
| QINLOCK ORAL TABLET 50 MG | 5 | PA; NMO; QL (90 EA per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA; NMO; QL (60 EA per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 100 MG, 200 MG | 5 | PA; NMO |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA; NMO |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA; NMO; QL (240 EA per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 50 MG, 70 MG, 80 MG | 5 | PA; NMO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|-------------------------------------|
| SPRYCEL ORAL TABLET 140 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| SPRYCEL ORAL TABLET 20 MG | 5 | PA; NMO; QL (90 EA per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA; NMO |
| SUTENT ORAL CAPSULE 12.5 MG, 25 MG, 37.5 MG, 50 MG | 5 | PA; NMO |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA; NMO |
| TAGRISSEO ORAL TABLET 40 MG, 80 MG | 5 | PA; LA; NMO |
| TALZENNA ORAL CAPSULE 0.25 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| TALZENNA ORAL CAPSULE 1 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA; NMO; QL (240 EA per 30 days) |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA; LA; NMO; QL (60 EA per 30 days) |
| TUKYSA ORAL TABLET 150 MG, 50 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| TURALIO ORAL CAPSULE 200 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| TYKERB ORAL TABLET 250 MG | 5 | NMO; QL (150 EA per 30 days) |
| VENCLEXTA ORAL TABLET 10 MG, 50 MG | 4 | PA; LA; NMO |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA; LA; NMO |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG | 3 | PA; LA; NMO |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA; LA; NMO |
| VITRAKVI ORAL CAPSULE 100 MG, 25 MG | 5 | PA; NMO |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA; NMO |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| VOTRIENT ORAL TABLET 200 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA; NMO; QL (60 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|---------------------------------|
| XOSPATA ORAL TABLET 40 MG | 5 | PA; LA; NMO |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA; NMO; QL (90 EA per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5 | NMO; QL (240 EA per 30 days) |
| ZYDELIG ORAL TABLET 100 MG | 5 | NMO; QL (90 EA per 30 days) |
| ZYDELIG ORAL TABLET 150 MG | 5 | NMO; QL (60 EA per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA; NMO |
| RETINOIDS | | |
| <i>bexarotene oral capsule 75 mg</i> | 5 | NMO |
| TARGRETIN EXTERNAL GEL 1 % | 5 | PA; NMO |
| <i>tretinoin oral capsule 10 mg</i> | 5 | NMO |
| ANTIPARASITICS | | |
| ANTHELMINTICS | | |
| <i>albendazole oral tablet 200 mg</i> | 4 | NMO |
| EMVERM ORAL TABLET CHEWABLE 100 MG | 4 | NMO |
| <i>ivermectin oral tablet 3 mg</i> | 2 | NMO |
| ANTIPROTOZOALS | | |
| ALINIA ORAL SUSPENSION RECONSTITUTED 100 MG/5ML | 4 | NMO; QL (150 ML per 30 days) |
| ALINIA ORAL TABLET 500 MG | 4 | NMO; QL (6 EA per 30 days) |
| <i>atovaquone oral suspension 750 mg/5ml</i> | 5 | NMO |
| <i>atovaquone-proguanil hcl oral tablet 250-100 mg, 62.5-25 mg</i> | 4 | NMO |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | |
| COARTEM ORAL TABLET 20-120 MG | 4 | NMO |
| <i>hydroxychloroquine sulfate oral tablet 200 mg</i> | 2 | |
| LAMPIT ORAL TABLET 120 MG, 30 MG | 4 | NMO |
| <i>mefloquine hcl oral tablet 250 mg</i> | 2 | |
| <i>pentamidine isethionate inhalation solution reconstituted 300 mg</i> | 4 | BD; NMO |
| <i>pentamidine isethionate injection solution reconstituted 300 mg</i> | 4 | NMO |
| <i>primaquine phosphate oral tablet 26.3 mg</i> | 4 | NMO |
| <i>pyrimethamine oral tablet 25 mg</i> | 5 | NMO |
| <i>quinine sulfate oral capsule 324 mg</i> | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|---------------------------------|
| ANTIPARKINSON AGENTS | | |
| ANTICHOLINERGICS | | |
| <i>benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | GC |
| <i>trihexyphenidyl hcl oral solution 0.4 mg/ml</i> | 2 | |
| <i>trihexyphenidyl hcl oral tablet 2 mg, 5 mg</i> | 1 | GC |
| ANTIPARKINSON AGENTS, OTHER | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | |
| <i>amantadine hcl oral syrup 50 mg/5ml</i> | 2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 4 | |
| <i>entacapone oral tablet 200 mg</i> | 2 | |
| DOPAMINE AGONISTS | | |
| APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE 30 MG/3ML | 5 | LA; NMO; QL (60 ML per 30 days) |
| <i>bromocriptine mesylate oral capsule 5 mg</i> | 2 | |
| <i>bromocriptine mesylate oral tablet 2.5 mg</i> | 2 | |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24HR, 2 MG/24HR, 3 MG/24HR, 4 MG/24HR, 6 MG/24HR, 8 MG/24HR | 4 | |
| <i>pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 1 | GC |
| <i>ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 1 | GC |
| DOPAMINE PRECURSORS AND/OR L-AMINO ACID DECARBOXYLASE INHIBITORS | | |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 1 | GC |
| <i>carbidopa-levodopa oral tablet dispersible 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | |
| INBRIJA INHALATION CAPSULE 42 MG | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95 MG, 36.25-145 MG, 48.75-195 MG, 61.25-245 MG | 4 | |
| MONOAMINE OXIDASE B (MAO-B) INHIBITORS | | |
| <i>rasagiline mesylate oral tablet 0.5 mg, 1 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | |
| ANTIPSYCHOTICS | | |
| 1ST GENERATION/TYPICAL | | |
| <i>chlorpromazine hcl oral tablet 10 mg, 25 mg</i> | 4 | BD |
| <i>chlorpromazine hcl oral tablet 100 mg, 200 mg, 50 mg</i> | 4 | |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 4 | NMO |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 4 | NMO |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5ml</i> | 2 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml 1 ml, 50 mg/ml, 50 mg/ml(1ml)</i> | 4 | NMO |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 4 | NMO |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 1 | GC |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>molindone hcl oral tablet 10 mg, 25 mg, 5 mg</i> | 2 | |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 4 | |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 4 | |
| <i>thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 3 | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 4 | |
| <i>trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 4 | |
| 2ND GENERATION/ATYPICAL | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|-----------------------------|
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG | 5 | NMO |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG | 5 | NMO |
| ABILIFY MYCITE ORAL TABLET 10 MG, 15 MG, 20 MG, 30 MG | 5 | NMO; QL (30 EA per 30 days) |
| ABILIFY MYCITE ORAL TABLET 2 MG, 5 MG | 5 | NMO; QL (60 EA per 30 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 4 | QL (750 ML per 30 days) |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 20 mg, 30 mg</i> | 3 | QL (30 EA per 30 days) |
| <i>aripiprazole oral tablet 2 mg, 5 mg</i> | 3 | QL (60 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 10 mg, 15 mg</i> | 5 | NMO; QL (60 EA per 30 days) |
| CAPLYTA ORAL CAPSULE 42 MG | 5 | NMO |
| FANAPT ORAL TABLET 1 MG, 2 MG, 4 MG | 4 | NMO |
| FANAPT ORAL TABLET 10 MG, 12 MG, 6 MG, 8 MG | 5 | NMO |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG | 4 | NMO |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML, 156 MG/ML, 234 MG/1.5ML, 78 MG/0.5ML | 5 | NMO |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML | 4 | NMO |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.875ML, 410 MG/1.315ML, 546 MG/1.75ML, 819 MG/2.625ML | 5 | NMO |
| LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG | 3 | |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA; LA; NMO |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA; LA; NMO |
| <i>olanzapine intramuscular solution reconstituted 10 mg</i> | 4 | NMO |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | 1 | GC |
| <i>olanzapine oral tablet dispersible 10 mg, 15 mg, 20 mg, 5 mg</i> | 4 | QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|------------------------------|
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 6 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>paliperidone er oral tablet extended release 24 hour 9 mg</i> | 5 | NMO; QL (30 EA per 30 days) |
| PERSERIS SUBCUTANEOUS PREFILLED SYRINGE 120 MG, 90 MG | 5 | NMO |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | 3 | |
| <i>quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | 1 | GC |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 5 | NMO |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5 MG, 25 MG | 4 | NMO |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 37.5 MG, 50 MG | 5 | NMO |
| <i>risperidone oral solution 1 mg/ml</i> | 2 | |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | GC |
| <i>risperidone oral tablet dispersible 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 4 | |
| SAPHRIS SUBLINGUAL TABLET SUBLINGUAL 10 MG, 2.5 MG, 5 MG | 4 | |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR | 5 | NMO |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5 | NMO |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3 MG | 4 | NMO |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>ziprasidone mesylate intramuscular solution reconstituted 20 mg</i> | 4 | NMO |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210 MG | 4 | NMO |
| TREATMENT-RESISTANT | | |
| <i>clozapine oral tablet 100 mg</i> | 3 | NMO; QL (270 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|------------------------------|
| <i>clozapine oral tablet 200 mg, 25 mg</i> | 3 | NMO; QL (120 EA per 30 days) |
| <i>clozapine oral tablet 50 mg</i> | 3 | NMO; QL (180 EA per 30 days) |
| <i>clozapine oral tablet dispersible 100 mg, 150 mg, 25 mg</i> | 4 | NMO; QL (270 EA per 30 days) |
| <i>clozapine oral tablet dispersible 12.5 mg</i> | 4 | NMO; QL (90 EA per 30 days) |
| <i>clozapine oral tablet dispersible 200 mg</i> | 5 | NMO; QL (120 EA per 30 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | NMO |
| ANTISPASTICITY AGENTS | | |
| ANTISPASTICITY AGENTS | | |
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | NMO; GC |
| <i>tizanidine hcl oral tablet 2 mg, 4 mg</i> | 1 | NMO; GC |
| ANTIVIRALS | | |
| ANTI-CYTOMEGALOVIRUS (CMV) AGENTS | | |
| <i>valganciclovir hcl oral solution reconstituted 50 mg/ml</i> | 4 | |
| <i>valganciclovir hcl oral tablet 450 mg</i> | 5 | NMO |
| ZIRGAN OPHTHALMIC GEL 0.15 % | 4 | NMO |
| ANTI-HEPATITIS B (HBV) AGENTS | | |
| <i>adefovir dipivoxil oral tablet 10 mg</i> | 5 | NMO; QL (30 EA per 30 days) |
| BARACLUDE ORAL SOLUTION 0.05 MG/ML | 5 | NMO; QL (600 ML per 30 days) |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 4 | QL (30 EA per 30 days) |
| EPIVIR HBV ORAL SOLUTION 5 MG/ML | 3 | |
| <i>lamivudine oral tablet 100 mg</i> | 3 | QL (90 EA per 30 days) |
| VEMLIDY ORAL TABLET 25 MG | 5 | NMO |
| ANTI-HEPATITIS C (HCV) AGENTS | | |
| MAVYRET ORAL TABLET 100-40 MG | 5 | PA; NMO |
| <i>ribavirin oral capsule 200 mg</i> | 4 | NMO |
| <i>ribavirin oral tablet 200 mg</i> | 4 | NMO |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | 5 | PA; NMO |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA; NMO |
| ANTIHERPETIC AGENTS | | |
| <i>acyclovir oral capsule 200 mg</i> | 1 | NMO; GC |
| <i>acyclovir oral suspension 200 mg/5ml</i> | 3 | NMO |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 1 | NMO; GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|------------------------------|
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 4 | BD; NMO |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | NMO |
| <i>trifluridine ophthalmic solution 1 %</i> | 3 | NMO |
| <i>valacyclovir hcl oral tablet 1 gm, 500 mg</i> | 2 | NMO |
| ANTI-HIV AGENTS, INTEGRASE INHIBITORS (INSTI) | | |
| BIKTARVY ORAL TABLET 50-200-25 MG | 5 | NMO; QL (30 EA per 30 days) |
| DOVATO ORAL TABLET 50-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | NMO; QL (60 EA per 30 days) |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | NMO; QL (60 EA per 30 days) |
| ISENTRESS ORAL PACKET 100 MG | 4 | QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET 400 MG | 5 | NMO; QL (120 EA per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG | 5 | NMO; QL (180 EA per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 25 MG | 4 | QL (180 EA per 30 days) |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| SYMTUZA ORAL TABLET 800-150-200-10 MG | 5 | NMO; QL (30 EA per 30 days) |
| TIVICAY ORAL TABLET 10 MG | 4 | QL (60 EA per 30 days) |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | NMO; QL (60 EA per 30 days) |
| TIVICAY PD ORAL TABLET SOLUBLE 5 MG | 4 | QL (360 EA per 30 days) |
| ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) | | |
| COMPLERA ORAL TABLET 200-25-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| EDURANT ORAL TABLET 25 MG | 5 | NMO; QL (30 EA per 30 days) |
| <i>efavirenz oral capsule 200 mg</i> | 4 | QL (120 EA per 30 days) |
| <i>efavirenz oral capsule 50 mg</i> | 4 | QL (480 EA per 30 days) |
| <i>efavirenz oral tablet 600 mg</i> | 5 | NMO; QL (30 EA per 30 days) |
| INTELENCE ORAL TABLET 100 MG | 5 | NMO; QL (120 EA per 30 days) |
| INTELENCE ORAL TABLET 200 MG | 5 | NMO; QL (60 EA per 30 days) |
| INTELENCE ORAL TABLET 25 MG | 4 | QL (120 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|-----------------------------|
| <i>nevirapine er oral tablet extended release 24 hour 100 mg</i> | 4 | QL (90 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>nevirapine oral suspension 50 mg/5ml</i> | 3 | QL (1200 ML per 30 days) |
| <i>nevirapine oral tablet 200 mg</i> | 3 | QL (60 EA per 30 days) |
| PIFELTRO ORAL TABLET 100 MG | 5 | NMO; QL (30 EA per 30 days) |
| ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) | | |
| <i>abacavir sulfate oral solution 20 mg/ml</i> | 4 | QL (960 ML per 30 days) |
| <i>abacavir sulfate oral tablet 300 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>abacavir sulfate-lamivudine oral tablet 600-300 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>abacavir-lamivudine-zidovudine oral tablet 300-150-300 mg</i> | 5 | NMO; QL (60 EA per 30 days) |
| ATRIPLA ORAL TABLET 600-200-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| CIMDUO ORAL TABLET 300-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| DESCOVY ORAL TABLET 200-25 MG | 5 | NMO; QL (30 EA per 30 days) |
| <i>didanosine oral capsule delayed release 250 mg, 400 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>efavirenz-emtricitab-tenofovir oral tablet 600-200-300 mg</i> | 5 | NMO; QL (30 EA per 30 days) |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300 mg, 600-300-300 mg</i> | 5 | NMO; QL (30 EA per 30 days) |
| <i>emtricitabine oral capsule 200 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>emtricitabine-tenofovir df oral tablet 200-300 mg</i> | 5 | NMO; QL (30 EA per 30 days) |
| EMTRIVA ORAL CAPSULE 200 MG | 4 | QL (30 EA per 30 days) |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | QL (680 ML per 28 days) |
| JULUCA ORAL TABLET 50-25 MG | 5 | NMO; QL (30 EA per 30 days) |
| <i>lamivudine oral solution 10 mg/ml</i> | 3 | QL (960 ML per 30 days) |
| <i>lamivudine oral tablet 150 mg</i> | 3 | QL (60 EA per 30 days) |
| <i>lamivudine oral tablet 300 mg</i> | 3 | QL (30 EA per 30 days) |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 4 | QL (60 EA per 30 days) |
| ODEFSEY ORAL TABLET 200-25-25 MG | 5 | NMO; QL (30 EA per 30 days) |
| <i>stavudine oral capsule 15 mg, 20 mg</i> | 4 | QL (120 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|------------------------------|
| <i>stavudine oral capsule 30 mg, 40 mg</i> | 4 | QL (60 EA per 30 days) |
| SYMFI LO ORAL TABLET 400-300-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| SYMFI ORAL TABLET 600-300-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 4 | QL (30 EA per 30 days) |
| TRUVADA ORAL TABLET 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| VIREAD ORAL POWDER 40 MG/GM | 5 | NMO; QL (240 GM per 30 days) |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG, 300 MG | 5 | NMO; QL (30 EA per 30 days) |
| <i>zidovudine oral capsule 100 mg</i> | 3 | QL (180 EA per 30 days) |
| <i>zidovudine oral syrup 50 mg/5ml</i> | 3 | QL (1680 ML per 28 days) |
| <i>zidovudine oral tablet 300 mg</i> | 3 | QL (60 EA per 30 days) |
| ANTI-HIV AGENTS, OTHER | | |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG | 5 | NMO; QL (60 EA per 30 days) |
| <i>rukobia oral tablet extended release 12 hour 600 mg</i> | 5 | NMO; QL (60 EA per 30 days) |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 4 | QL (1800 ML per 30 days) |
| SELZENTRY ORAL TABLET 150 MG | 5 | NMO; QL (240 EA per 30 days) |
| SELZENTRY ORAL TABLET 25 MG | 3 | QL (120 EA per 30 days) |
| SELZENTRY ORAL TABLET 300 MG | 5 | NMO; QL (120 EA per 30 days) |
| SELZENTRY ORAL TABLET 75 MG | 5 | NMO; QL (60 EA per 30 days) |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | NMO; QL (30 EA per 30 days) |
| TYBOST ORAL TABLET 150 MG | 4 | QL (30 EA per 30 days) |
| ANTI-HIV AGENTS, PROTEASE INHIBITORS (PI) | | |
| APTIVUS ORAL CAPSULE 250 MG | 5 | NMO; QL (120 EA per 30 days) |
| APTIVUS ORAL SOLUTION 100 MG/ML | 5 | NMO; QL (285 ML per 28 days) |
| <i>atazanavir sulfate oral capsule 150 mg, 200 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 300 mg</i> | 4 | QL (30 EA per 30 days) |
| CRIXIVAN ORAL CAPSULE 200 MG | 3 | QL (450 EA per 30 days) |
| CRIXIVAN ORAL CAPSULE 400 MG | 3 | QL (270 EA per 30 days) |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | NMO; QL (30 EA per 30 days) |
| <i>fosamprenavir calcium oral tablet 700 mg</i> | 5 | NMO; QL (120 EA per 30 days) |
| INVIRASE ORAL TABLET 500 MG | 5 | NMO; QL (120 EA per 30 days) |
| KALETRA ORAL TABLET 100-25 MG | 3 | QL (300 EA per 30 days) |
| KALETRA ORAL TABLET 200-50 MG | 3 | QL (150 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|------------------------------|
| LEXIVA ORAL SUSPENSION 50 MG/ML | 3 | QL (1575 ML per 28 days) |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5ml</i> | 4 | |
| NORVIR ORAL PACKET 100 MG | 4 | QL (360 EA per 30 days) |
| NORVIR ORAL SOLUTION 80 MG/ML | 4 | QL (480 ML per 30 days) |
| PREZCOBIX ORAL TABLET 800-150 MG | 5 | NMO; QL (30 EA per 30 days) |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | NMO; QL (360 ML per 30 days) |
| PREZISTA ORAL TABLET 150 MG | 4 | QL (240 EA per 30 days) |
| PREZISTA ORAL TABLET 600 MG | 5 | NMO; QL (60 EA per 30 days) |
| PREZISTA ORAL TABLET 75 MG | 4 | QL (480 EA per 30 days) |
| PREZISTA ORAL TABLET 800 MG | 5 | NMO; QL (30 EA per 30 days) |
| REYATAZ ORAL PACKET 50 MG | 5 | NMO; QL (180 EA per 30 days) |
| <i>ritonavir oral tablet 100 mg</i> | 4 | QL (360 EA per 30 days) |
| VIRACEPT ORAL TABLET 250 MG | 5 | NMO; QL (300 EA per 30 days) |
| VIRACEPT ORAL TABLET 625 MG | 5 | NMO; QL (120 EA per 30 days) |
| ANTI-INFLUENZA AGENTS | | |
| <i>oseltamivir phosphate oral capsule 30 mg, 45 mg, 75 mg</i> | 3 | NMO |
| <i>oseltamivir phosphate oral suspension reconstituted 6 mg/ml</i> | 3 | NMO |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/BLISTER | 4 | NMO |
| <i>rimantadine hcl oral tablet 100 mg</i> | 4 | NMO |
| XOFLUZA (40 MG DOSE) ORAL TABLET THERAPY PACK 2 X 20 MG | 3 | NMO |
| XOFLUZA (80 MG DOSE) ORAL TABLET THERAPY PACK 2 X 40 MG | 3 | NMO |
| ANXIOLYTICS | | |
| ANXIOLYTICS, OTHER | | |
| <i>buspirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | NMO; GC |
| <i>hydroxyzine hcl oral syrup 10 mg/5ml</i> | 4 | NMO |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 1 | NMO; GC |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | NMO; GC |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 2 | NMO; QL (120 EA per 30 days) |
| BENZODIAZEPINES | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------------|
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 2 | NMO; QL (120 EA per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | 2 | NMO; QL (300 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 2 mg</i> | 2 | NMO; QL (300 EA per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 2 | NMO; QL (180 EA per 30 days) |
| <i>diazepam oral concentrate 5 mg/ml</i> | 2 | NMO; QL (240 ML per 30 days) |
| <i>diazepam oral solution 5 mg/5ml</i> | 2 | NMO; QL (1200 ML per 30 days) |
| <i>diazepam oral tablet 10 mg</i> | 1 | NMO; GC; QL (120 EA per 30 days) |
| <i>diazepam oral tablet 2 mg</i> | 1 | NMO; GC; QL (600 EA per 30 days) |
| <i>diazepam oral tablet 5 mg</i> | 1 | NMO; GC; QL (240 EA per 30 days) |
| LORAZEPAM INTENSOL ORAL CONCENTRATE 2 MG/ML | 2 | NMO; QL (240 ML per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | NMO; GC; QL (150 EA per 30 days) |
| BIPOLAR AGENTS | | |
| MOOD STABILIZERS | | |
| <i>divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg</i> | 2 | |
| <i>divalproex sodium oral capsule delayed release sprinkle 125 mg</i> | 2 | |
| <i>divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg</i> | 1 | GC |
| <i>lithium carbonate er oral tablet extended release 300 mg, 450 mg</i> | 1 | GC |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | GC |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | GC |
| <i>lithium oral solution 8 meq/5ml</i> | 1 | GC |
| BLOOD GLUCOSE REGULATORS | | |
| ANTIDIABETIC AGENTS | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|-----------------------------|
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | GC |
| CYCLOSET ORAL TABLET 0.8 MG | 6 | |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | 6 | GC |
| <i>glipizide er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 6 | GC |
| <i>glipizide oral tablet 10 mg, 5 mg</i> | 6 | GC |
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> | 6 | GC |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 6 | GC |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 6 | GC |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 6 | GC |
| INVOKAMET ORAL TABLET 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG | 6 | |
| INVOKAMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG | 6 | |
| INVOKANA ORAL TABLET 100 MG, 300 MG | 6 | |
| JANUMET ORAL TABLET 50-1000 MG, 50-500 MG | 6 | QL (60 EA per 30 days) |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG | 6 | QL (30 EA per 30 days) |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 50-1000 MG, 50-500 MG | 6 | QL (60 EA per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 6 | QL (30 EA per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 6 | |
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg</i> | 6 | GC; QL (120 EA per 30 days) |
| <i>metformin hcl er oral tablet extended release 24 hour 750 mg</i> | 6 | GC; QL (90 EA per 30 days) |
| <i>metformin hcl oral solution 500 mg/5ml</i> | 6 | GC |
| <i>metformin hcl oral tablet 1000 mg, 500 mg, 850 mg</i> | 6 | GC |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 6 | GC |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML | 6 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|--------------------------------------|
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML | 6 | |
| <i>pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg</i> | 6 | GC |
| <i>pioglitazone hcl-glimepiride oral tablet 30-2 mg, 30-4 mg</i> | 6 | GC |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg</i> | 6 | GC |
| <i>repaglinide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 6 | GC |
| RIOMET ER ORAL SUSPENSION RECONSTITUTED ER 500 MG/5ML | 6 | |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 6 | |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700 MCG/2.7ML | 6 | PA |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 1500 MCG/1.5ML | 6 | PA |
| SYNJARDY ORAL TABLET 12.5-1000 MG, 12.5-500 MG, 5-1000 MG, 5-500 MG | 6 | |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 25-1000 MG, 5-1000 MG | 6 | |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML | 6 | |
| VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18 MG/3ML | 6 | |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML | 6 | SSM |
| GLYCEMIC AGENTS | | |
| BAQSIMI TWO PACK NASAL POWDER 3 MG/DOSE | 3 | NMO |
| <i>diazoxide oral suspension 50 mg/ml</i> | 4 | |
| GLUCAGEN HYPOKIT INJECTION SOLUTION RECONSTITUTED 1 MG | 6 | NMO |
| <i>glucagon emergency injection kit 1 mg</i> | 6 | GC; NMO |
| KORLYM ORAL TABLET 300 MG | 5 | PA; LA; NMO; QL (120 EA per 30 days) |
| INSULINS | | |
| ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML | 6 | GC; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML | 6 | GC; NMO |
| <i>cvs gauze sterile pad 2"x2"</i> | 6 | GC; NMO |
| EXEL COMFORT POINT PEN NEEDLE 29G X 12MM | 6 | GC; NMO |
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 6 | SSM |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 6 | SSM |
| FIASP SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | SSM |
| <i>insulin asp prot & asp flexpen subcutaneous suspension pen-injector (70-30) 100 unit/ml</i> | 6 | SSM |
| <i>insulin aspart flexpen subcutaneous solution pen-injector 100 unit/ml</i> | 6 | SSM |
| <i>insulin aspart penfill subcutaneous solution cartridge 100 unit/ml</i> | 6 | SSM |
| <i>insulin aspart prot & aspart subcutaneous suspension (70-30) 100 unit/ml</i> | 6 | SSM |
| <i>insulin aspart subcutaneous solution 100 unit/ml</i> | 6 | SSM |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 6 | SSM |
| LANTUS SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | SSM |
| LEVEMIR FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 6 | SSM |
| LEVEMIR SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | SSM |
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 6 | SSM |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 6 | SSM |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML | 6 | SSM |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 6 | SSM |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML | 6 | SSM |
| NOVOLIN R INJECTION SOLUTION 100 UNIT/ML | 6 | SSM |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 6 | SSM |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 6 | SSM |
| NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 6 | SSM |
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 6 | SSM |
| NOVOLOG SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | SSM |
| <i>preferred plus insulin syringe 28g x 1/2" 0.5 ml</i> | 6 | GC; NMO |
| RELI-ON INSULIN SYRINGE 29G 0.3 ML | 6 | GC; NMO |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML | 6 | SSM |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 6 | SSM |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 6 | SSM |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML | 6 | SSM |
| TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | SSM |
| BLOOD PRODUCTS AND MODIFIERS | | |
| ANTICOAGULANTS | | |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG | 3 | |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG | 3 | |
| <i>enoxaparin sodium subcutaneous solution 100 mg/ml, 120 mg/0.8ml, 150 mg/ml, 30 mg/0.3ml, 40 mg/0.4ml, 60 mg/0.6ml, 80 mg/0.8ml</i> | 4 | NMO |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml, 5 mg/0.4ml, 7.5 mg/0.6ml</i> | 5 | NMO |
| <i>fondaparinux sodium subcutaneous solution 2.5 mg/0.5ml</i> | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------------|
| FRAGMIN SUBCUTANEOUS SOLUTION 10000 UNIT/ML, 12500 UNIT/0.5ML, 15000 UNIT/0.6ML, 18000 UNT/0.72ML, 7500 UNIT/0.3ML, 95000 UNIT/3.8ML | 5 | NMO |
| FRAGMIN SUBCUTANEOUS SOLUTION 2500 UNIT/0.2ML, 5000 UNIT/0.2ML | 4 | NMO |
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml</i> | 3 | NMO |
| JANTOVEN ORAL TABLET 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG | 1 | GC |
| <i>warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | GC |
| XARELTO ORAL TABLET 10 MG, 15 MG, 2.5 MG, 20 MG | 3 | |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG | 3 | NMO |
| BLOOD PRODUCTS AND MODIFIERS, OTHER | | |
| <i>anagrelide hcl oral capsule 0.5 mg, 1 mg</i> | 2 | |
| PROMACTA ORAL PACKET 12.5 MG | 5 | PA; NMO; QL (360 EA per 30 days) |
| PROMACTA ORAL PACKET 25 MG | 5 | PA; NMO; QL (180 EA per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML | 4 | PA; NMO |
| <i>tranexamic acid oral tablet 650 mg</i> | 3 | NMO |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML | 5 | PA; NMO |
| ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML | 5 | PA; NMO |
| PLATELET MODIFYING AGENTS | | |
| <i>aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg</i> | 2 | |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | |
| CABLIVI INJECTION KIT 11 MG | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 1 | GC |
| <i>clopidogrel bisulfate oral tablet 75 mg</i> | 1 | GC |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 1 | GC |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> | 4 | |
| CARDIOVASCULAR AGENTS | | |
| ALPHA-ADRENERGIC AGONISTS | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 6 | GC |
| <i>clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | 6 | GC |
| <i>guanfacine hcl oral tablet 1 mg, 2 mg</i> | 6 | GC |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | 6 | GC |
| <i>midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg</i> | 6 | GC; NMO |
| NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG | 5 | PA; NMO |
| ALPHA-ADRENERGIC BLOCKING AGENTS | | |
| <i>doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | 6 | GC |
| <i>prazosin hcl oral capsule 1 mg, 2 mg, 5 mg</i> | 6 | GC |
| <i>terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 6 | GC |
| ANGIOTENSIN II RECEPTOR ANTAGONISTS | | |
| <i>candesartan cilexetil oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 6 | GC |
| EDARBI ORAL TABLET 40 MG, 80 MG | 6 | |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 6 | GC |
| <i>losartan potassium oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg</i> | 6 | GC |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 6 | GC |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | 6 | GC |
| ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS | | |
| <i>benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 6 | GC |
| <i>fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | GC |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 6 | GC |
| <i>moexipril hcl oral tablet 15 mg, 7.5 mg</i> | 6 | GC |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 6 | GC |
| QBRELIS ORAL SOLUTION 1 MG/ML | 6 | |
| <i>quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | GC |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 6 | GC |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 6 | GC |
| ANTIARRHYTHMICS | | |
| <i>amiodarone hcl oral tablet 100 mg, 400 mg</i> | 2 | |
| <i>amiodarone hcl oral tablet 200 mg</i> | 1 | GC |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | 2 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 4 | |
| <i>flecainide acetate oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | GC |
| <i>mexiletine hcl oral capsule 150 mg, 200 mg, 250 mg</i> | 2 | |
| MULTAQ ORAL TABLET 400 MG | 3 | |
| PACERONE ORAL TABLET 100 MG, 200 MG | 1 | GC |
| PACERONE ORAL TABLET 400 MG | 2 | |
| <i>propafenone hcl er oral capsule extended release 12 hour 225 mg, 325 mg, 425 mg</i> | 4 | |
| <i>propafenone hcl oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 2 | |
| <i>sotalol hcl (af) oral tablet 120 mg, 160 mg, 80 mg</i> | 1 | GC |
| <i>sotalol hcl oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| BETA-ADRENERGIC BLOCKING AGENTS | | |
| <i>acebutolol hcl oral capsule 200 mg, 400 mg</i> | 6 | GC |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>betaxolol hcl oral tablet 10 mg, 20 mg</i> | 6 | GC |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 6 | GC |
| BYSTOLIC ORAL TABLET 10 MG, 2.5 MG, 20 MG, 5 MG | 6 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 6 | GC |
| <i>carvedilol phosphate er oral capsule extended release 24 hour 10 mg, 20 mg, 40 mg, 80 mg</i> | 6 | GC |
| <i>labetalol hcl oral tablet 100 mg, 200 mg, 300 mg</i> | 6 | GC |
| <i>metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 6 | GC |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 6 | GC |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 6 | GC |
| <i>propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg</i> | 6 | GC |
| <i>propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml</i> | 6 | GC |
| <i>propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 60 mg</i> | 6 | GC |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 6 | GC |
| CALCIUM CHANNEL BLOCKING AGENTS, DIHYDROPYRIDINES | | |
| <i>amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 6 | GC |
| <i>felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 6 | GC |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 6 | GC |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 4 | |
| <i>nicardipine hcl oral capsule 20 mg, 30 mg</i> | 6 | GC |
| <i>nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg</i> | 6 | GC |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg</i> | 6 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | 6 | GC |
| <i>nimodipine oral capsule 30 mg</i> | 6 | GC; NMO |
| <i>nisoldipine er oral tablet extended release 24 hour 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg, 8.5 mg</i> | 6 | GC |
| NYMALIZE ORAL SOLUTION 6 MG/ML | 6 | NMO |
| CALCIUM CHANNEL BLOCKING AGENTS, NONDIHYDROPYRIDINES | | |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG | 6 | |
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 360 mg, 420 mg</i> | 6 | GC |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg</i> | 6 | GC |
| <i>diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg</i> | 6 | GC |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | 6 | GC |
| <i>dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 6 | |
| MATZIM LA ORAL TABLET EXTENDED RELEASE 24 HOUR 180 MG, 240 MG, 300 MG, 360 MG, 420 MG | 6 | |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG, 360 MG | 6 | |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG | 6 | |
| <i>verapamil hcl er oral capsule extended release 24 hour 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg</i> | 6 | GC |
| <i>verapamil hcl er oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 6 | GC |
| <i>verapamil hcl oral tablet 120 mg, 40 mg, 80 mg</i> | 6 | GC |
| VERELAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 360 MG | 6 | |
| CARDIOVASCULAR AGENTS, OTHER | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| ALDACTAZIDE ORAL TABLET 50-50 MG | 6 | |
| <i>aliskiren fumarate oral tablet 150 mg, 300 mg</i> | 6 | GC |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 6 | GC |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | 6 | GC |
| <i>amlodipine besylate-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | 6 | GC |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 6 | GC |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 6 | GC |
| <i>amlodipine-valsartan-hctz oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | 6 | GC |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 6 | GC |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 6 | GC |
| BIDIL ORAL TABLET 20-37.5 MG | 6 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 6 | GC |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 6 | GC |
| <i>captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg</i> | 6 | GC |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG | 6 | PA; QL (60 EA per 30 days) |
| DEMSEER ORAL CAPSULE 250 MG | 5 | NMO |
| DIGITEK ORAL TABLET 125 MCG, 250 MCG | 6 | |
| DIGOX ORAL TABLET 125 MCG, 250 MCG | 6 | |
| <i>digoxin oral solution 0.05 mg/ml</i> | 6 | GC |
| <i>digoxin oral tablet 125 mcg, 250 mcg</i> | 6 | GC |
| DUTOPROL ORAL TABLET EXTENDED RELEASE 24 HOUR 100-12.5 MG, 25-12.5 MG, 50-12.5 MG | 6 | |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG | 6 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 6 | GC |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG | 6 | PA; QL (60 EA per 30 days) |
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg</i> | 6 | GC |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 6 | GC |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 6 | GC |
| <i>losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 6 | GC |
| <i>methyldopa-hydrochlorothiazide oral tablet 250-15 mg, 250-25 mg</i> | 6 | GC |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 6 | GC |
| <i>metyrosine oral capsule 250 mg</i> | 5 | NMO |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 6 | GC |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 6 | GC |
| <i>pentoxifylline er oral tablet extended release 400 mg</i> | 1 | GC |
| <i>propranolol-hctz oral tablet 40-25 mg, 80-25 mg</i> | 6 | GC |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 6 | GC |
| <i>ranolazine er oral tablet extended release 12 hour 1000 mg, 500 mg</i> | 6 | GC |
| <i>spironolactone-hctz oral tablet 25-25 mg</i> | 6 | GC |
| TEKTURNA HCT ORAL TABLET 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG | 6 | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | 6 | GC |
| <i>telmisartan-hctz oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | 6 | GC |
| <i>trandolapril-verapamil hcl er oral tablet extended release 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg</i> | 6 | GC |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i> | 6 | GC |
| <i>triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg</i> | 6 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 6 | GC |
| DIURETICS, LOOP | | |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 6 | GC; NMO |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 6 | GC |
| <i>ethacrynic acid oral tablet 25 mg</i> | 6 | GC |
| <i>furosemide injection solution 10 mg/ml, 10 mg/ml (4ml syringe)</i> | 6 | GC; NMO |
| <i>furosemide oral solution 10 mg/ml, 8 mg/ml</i> | 6 | GC |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 6 | GC |
| <i>torseamide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 6 | GC |
| DIURETICS, POTASSIUM-SPARING | | |
| <i>amiloride hcl oral tablet 5 mg</i> | 6 | GC |
| CAROSPIR ORAL SUSPENSION 25 MG/5ML | 6 | |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 6 | GC |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>triamterene oral capsule 100 mg, 50 mg</i> | 6 | GC |
| DIURETICS, THIAZIDE | | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 6 | GC |
| DIURIL ORAL SUSPENSION 250 MG/5ML | 6 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 6 | GC |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 6 | GC |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 6 | GC |
| DYSLIPIDEMICS, FIBRIC ACID DERIVATIVES | | |
| <i>fenofibrate micronized oral capsule 130 mg, 200 mg, 43 mg, 67 mg</i> | 6 | GC |
| <i>fenofibrate oral capsule 134 mg, 150 mg, 50 mg</i> | 6 | GC |
| <i>fenofibrate oral tablet 120 mg, 145 mg, 160 mg, 40 mg, 48 mg, 54 mg</i> | 6 | GC |
| <i>fenofibric acid oral capsule delayed release 135 mg, 45 mg</i> | 6 | GC |
| <i>gemfibrozil oral tablet 600 mg</i> | 1 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| DYSLIPIDEMICS, HMG COA REDUCTASE INHIBITORS | | |
| <i>atorvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 6 | GC |
| <i>flolipid oral suspension 20 mg/5ml, 40 mg/5ml</i> | 6 | |
| <i>fluvastatin sodium er oral tablet extended release 24 hour 80 mg</i> | 6 | GC |
| <i>fluvastatin sodium oral capsule 20 mg, 40 mg</i> | 6 | GC |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG | 6 | |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | GC |
| <i>pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 6 | GC |
| <i>rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | GC |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | 6 | GC |
| ZYPITAMAG ORAL TABLET 2 MG, 4 MG | 3 | |
| DYSLIPIDEMICS, OTHER | | |
| <i>cholestyramine light oral powder 4 gm/dose</i> | 2 | |
| <i>cholestyramine oral packet 4 gm</i> | 2 | |
| <i>colestipol hcl oral packet 5 gm</i> | 2 | |
| <i>colestipol hcl oral tablet 1 gm</i> | 2 | |
| <i>ezetimibe oral tablet 10 mg</i> | 2 | |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | 6 | GC |
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg</i> | 2 | |
| NIACOR ORAL TABLET 500 MG | 2 | NMO |
| <i>omega-3-acid ethyl esters oral capsule 1 gm</i> | 2 | |
| PREVALITE ORAL PACKET 4 GM | 6 | |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML | 4 | PA |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML | 4 | PA |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML | 4 | PA |
| VASCEPA ORAL CAPSULE 0.5 GM | 4 | QL (240 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| VASCEPA ORAL CAPSULE 1 GM | 4 | QL (120 EA per 30 days) |
| WELCHOL ORAL TABLET 625 MG | 3 | |
| VASODILATORS, DIRECT-ACTING ARTERIAL/ VENOUS | | |
| <i>hydralazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | 6 | GC |
| <i>isosorbide mononitrate er oral tablet extended release 24 hour 120 mg, 30 mg, 60 mg</i> | 6 | GC |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 6 | GC |
| MINITRAN TRANSDERMAL PATCH 24 HOUR 0.1 MG/HR, 0.2 MG/HR, 0.4 MG/HR, 0.6 MG/HR | 6 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 6 | GC |
| NITRO-BID TRANSDERMAL OINTMENT 2 % | 6 | |
| NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.3 MG/HR, 0.8 MG/HR | 6 | |
| <i>nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg, 0.6 mg</i> | 6 | GC |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 6 | GC |
| <i>nitroglycerin translingual solution 0.4 mg/spray</i> | 6 | GC |
| RECTIV RECTAL OINTMENT 0.4 % | 4 | NMO |
| CENTRAL NERVOUS SYSTEM AGENTS | | |
| ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES | | |
| <i>amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 5 mg</i> | 3 | PA |
| <i>amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | |
| <i>dextroamphetamine sulfate oral solution 5 mg/5ml</i> | 4 | PA |
| <i>dextroamphetamine sulfate oral tablet 10 mg, 5 mg</i> | 4 | PA |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------------|
| ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, NON-AMPHETAMINES | | |
| <i>atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>atomoxetine hcl oral capsule 100 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg</i> | 4 | |
| <i>methylphenidate hcl er oral tablet extended release 10 mg, 18 mg, 20 mg, 27 mg, 36 mg, 54 mg</i> | 4 | PA |
| <i>methylphenidate hcl er oral tablet extended release 24 hour 18 mg, 27 mg, 36 mg, 54 mg</i> | 4 | PA |
| <i>methylphenidate hcl oral solution 10 mg/5ml, 5 mg/5ml</i> | 4 | PA |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | PA |
| CENTRAL NERVOUS SYSTEM, OTHER | | |
| AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG | 5 | PA; NMO; QL (120 EA per 30 days) |
| EVRYSDI ORAL SOLUTION RECONSTITUTED 0.75 MG/ML | 5 | PA; NMO |
| FIRDAPSE ORAL TABLET 10 MG | 5 | PA; NMO |
| NUEDEXTA ORAL CAPSULE 20-10 MG | 3 | PA |
| <i>riluzole oral tablet 50 mg</i> | 4 | |
| <i>tetrabenazine oral tablet 12.5 mg</i> | 5 | PA; NMO; QL (90 EA per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | 5 | PA; NMO; QL (120 EA per 30 days) |
| TIGLUTIK ORAL SUSPENSION 50 MG/10ML | 5 | NMO |
| FIBROMYALGIA AGENTS | | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg</i> | 3 | |
| <i>pregabalin oral solution 20 mg/ml</i> | 3 | |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 3 | |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50 MG | 3 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|---------------------------------|
| MULTIPLE SCLEROSIS AGENTS | | |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML | 5 | PA; NMO |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML | 5 | PA; NMO |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NMO |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML, 40 MG/ML | 5 | PA; NMO |
| <i>dalfampridine er oral tablet extended release 12 hour 10 mg</i> | 5 | PA; NMO; QL (60 EA per 30 days) |
| <i>dimethyl fumarate oral capsule delayed release 120 mg, 240 mg</i> | 5 | PA; NMO |
| GILENYA ORAL CAPSULE 0.5 MG | 5 | PA; NMO |
| <i>glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml</i> | 5 | PA; NMO |
| KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 20 MG/0.4ML | 5 | PA; NMO |
| MAYZENT ORAL TABLET 0.25 MG, 2 MG | 5 | PA; NMO |
| TECFIDERA ORAL 120 & 240 MG | 5 | PA; NMO |
| TECFIDERA ORAL CAPSULE DELAYED RELEASE 120 MG, 240 MG | 5 | PA; NMO |
| DENTAL AND ORAL AGENTS | | |
| DENTAL AND ORAL AGENTS | | |
| <i>cevimeline hcl oral capsule 30 mg</i> | 4 | |
| <i>chlorhexidine gluconate mouth/throat solution 0.12 %</i> | 1 | NMO; GC |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | 2 | |
| <i>triamcinolone acetonide mouth/throat paste 0.1 %</i> | 2 | NMO |
| DERMATOLOGICAL AGENTS | | |
| ACNE AND ROSACEA AGENTS | | |
| <i>acitretin oral capsule 10 mg, 25 mg</i> | 4 | NMO |
| <i>acitretin oral capsule 17.5 mg</i> | 5 | NMO |
| AMNESTEEM ORAL CAPSULE 10 MG, 20 MG, 40 MG | 4 | NMO |
| <i>benzoyl peroxide-erythromycin external gel 5-3 %</i> | 2 | NMO |
| CLARAVIS ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 4 | NMO |
| <i>tazarotene external cream 0.1 %</i> | 4 | NMO |
| TAZORAC EXTERNAL CREAM 0.05 % | 4 | NMO |
| TAZORAC EXTERNAL GEL 0.05 %, 0.1 % | 4 | NMO |
| <i>tretinoin external cream 0.025 %, 0.05 %, 0.1 %</i> | 3 | NMO |
| <i>tretinoin external gel 0.01 %, 0.025 %</i> | 4 | NMO |
| DERMATITIS AND PRUITUS AGENTS | | |
| <i>alclometasone dipropionate external cream 0.05 %</i> | 2 | NMO |
| <i>alclometasone dipropionate external ointment 0.05 %</i> | 2 | NMO |
| <i>ammonium lactate external cream 12 %</i> | 1 | NMO; GC |
| <i>ammonium lactate external lotion 12 %</i> | 3 | NMO |
| <i>betamethasone dipropionate aug external cream 0.05 %</i> | 2 | NMO |
| <i>betamethasone dipropionate aug external gel 0.05 %</i> | 2 | NMO |
| <i>betamethasone dipropionate aug external lotion 0.05 %</i> | 2 | NMO |
| <i>betamethasone dipropionate aug external ointment 0.05 %</i> | 2 | NMO |
| <i>betamethasone dipropionate external cream 0.05 %</i> | 2 | NMO |
| <i>betamethasone dipropionate external lotion 0.05 %</i> | 2 | NMO |
| <i>betamethasone dipropionate external ointment 0.05 %</i> | 2 | NMO |
| <i>betamethasone valerate external cream 0.1 %</i> | 3 | NMO |
| <i>betamethasone valerate external lotion 0.1 %</i> | 3 | NMO |
| <i>betamethasone valerate external ointment 0.1 %</i> | 3 | NMO |
| <i>clobetasol propionate emulsion external foam 0.05 %</i> | 4 | NMO |
| <i>clobetasol propionate external cream 0.05 %</i> | 4 | NMO |
| <i>clobetasol propionate external ointment 0.05 %</i> | 4 | NMO |
| <i>clobetasol propionate external solution 0.05 %</i> | 2 | NMO |
| <i>desonide external cream 0.05 %</i> | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>desonide external ointment 0.05 %</i> | 2 | NMO |
| <i>desoximetasone external cream 0.25 %</i> | 4 | NMO |
| <i>desoximetasone external gel 0.05 %</i> | 4 | NMO |
| <i>desoximetasone external ointment 0.05 %, 0.25 %</i> | 4 | NMO |
| EUCRISA EXTERNAL OINTMENT 2 % | 4 | NMO |
| <i>fluocinolone acetonide external cream 0.01 %, 0.025 %</i> | 2 | NMO |
| <i>fluocinolone acetonide external ointment 0.025 %</i> | 2 | NMO |
| <i>fluocinolone acetonide external solution 0.01 %</i> | 4 | NMO |
| <i>fluocinolone acetonide scalp external oil 0.01 %</i> | 4 | NMO |
| <i>fluocinonide emulsified base external cream 0.05 %</i> | 2 | NMO |
| <i>fluocinonide external gel 0.05 %</i> | 2 | NMO |
| <i>fluocinonide external ointment 0.05 %</i> | 2 | NMO |
| <i>fluocinonide external solution 0.05 %</i> | 2 | NMO |
| <i>fluticasone propionate external cream 0.05 %</i> | 1 | NMO; GC |
| <i>fluticasone propionate external ointment 0.005 %</i> | 2 | NMO |
| <i>halobetasol propionate external cream 0.05 %</i> | 4 | NMO |
| <i>halobetasol propionate external ointment 0.05 %</i> | 4 | NMO |
| <i>hydrocortisone external cream 1 %, 2.5 %</i> | 1 | NMO; GC |
| <i>hydrocortisone external lotion 2.5 %</i> | 2 | NMO |
| <i>hydrocortisone external ointment 1 %, 2.5 %</i> | 1 | NMO; GC |
| <i>hydrocortisone valerate external cream 0.2 %</i> | 4 | NMO |
| <i>hydrocortisone valerate external ointment 0.2 %</i> | 4 | NMO |
| <i>mometasone furoate external cream 0.1 %</i> | 2 | NMO |
| <i>mometasone furoate external ointment 0.1 %</i> | 2 | NMO |
| <i>mometasone furoate external solution 0.1 %</i> | 2 | NMO |
| <i>pimecrolimus external cream 1 %</i> | 4 | NMO |
| PROCTO-MED HC EXTERNAL CREAM 2.5 % | 2 | NMO |
| PROCTO-PAK EXTERNAL CREAM 1 % | 2 | NMO |
| PROCTOSOL HC EXTERNAL CREAM 2.5 % | 2 | NMO |
| PROCTOZONE-HC EXTERNAL CREAM 2.5 % | 2 | NMO |
| <i>selenium sulfide external lotion 2.5 %</i> | 2 | NMO |
| <i>tacrolimus external ointment 0.03 %, 0.1 %</i> | 4 | NMO |
| <i>triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %</i> | 2 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| <i>triamcinolone acetonide external lotion 0.025 %, 0.1 %</i> | 2 | NMO |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 %</i> | 1 | NMO; GC |
| DERMATOLOGICAL AGENTS, OTHER | | |
| <i>calcipotriene external cream 0.005 %</i> | 4 | NMO |
| <i>calcipotriene external ointment 0.005 %</i> | 4 | NMO |
| <i>calcipotriene external solution 0.005 %</i> | 4 | NMO |
| <i>calcitriol external ointment 3 mcg/gm</i> | 3 | NMO |
| <i>clotrimazole-betamethasone external cream 1-0.05 %</i> | 2 | NMO |
| <i>clotrimazole-betamethasone external lotion 1-0.05 %</i> | 4 | NMO |
| FLUOROPLEX EXTERNAL CREAM 1 % | 4 | NMO |
| <i>fluorouracil external cream 5 %</i> | 4 | NMO |
| <i>fluorouracil external solution 2 %, 5 %</i> | 2 | NMO |
| <i>global alcohol prep ease pad 70 %</i> | 6 | GC; NMO |
| <i>hydrocortisone ace-pramoxine external cream 1-1 %</i> | 2 | NMO |
| <i>imiquimod external cream 5 %</i> | 3 | NMO |
| <i>methoxsalen rapid oral capsule 10 mg</i> | 5 | NMO |
| <i>nystatin-triamcinolone external cream 100000-0.1 unit/gm-%</i> | 4 | NMO |
| <i>nystatin-triamcinolone external ointment 100000-0.1 unit/gm-%</i> | 4 | NMO |
| PICATO EXTERNAL GEL 0.015 %, 0.05 % | 4 | NMO |
| <i>podofilox external solution 0.5 %</i> | 2 | NMO |
| REGANEX EXTERNAL GEL 0.01 % | 5 | PA; NMO |
| SANTYL EXTERNAL OINTMENT 250 UNIT/GM | 4 | NMO |
| <i>silver sulfadiazine external cream 1 %</i> | 3 | NMO |
| SSD EXTERNAL CREAM 1 % | 1 | NMO; GC |
| PEDICULICIDES/SCABICIDES | | |
| <i>malathion external lotion 0.5 %</i> | 4 | NMO |
| <i>permethrin external cream 5 %</i> | 3 | NMO |
| TOPICAL ANTI-INFECTIVES | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>acyclovir external cream 5 %</i> | 4 | NMO |
| <i>acyclovir external ointment 5 %</i> | 4 | NMO |
| <i>ciclopirox external gel 0.77 %</i> | 2 | NMO |
| <i>ciclopirox external solution 8 %</i> | 2 | NMO |
| <i>clindamycin phosphate external gel 1 %</i> | 2 | NMO |
| <i>clindamycin phosphate external lotion 1 %</i> | 2 | NMO |
| <i>clindamycin phosphate external solution 1 %</i> | 2 | NMO |
| <i>ery external pad 2 %</i> | 2 | NMO |
| <i>erythromycin external gel 2 %</i> | 2 | NMO |
| <i>erythromycin external solution 2 %</i> | 2 | NMO |
| <i>mupirocin external ointment 2 %</i> | 1 | NMO; GC |
| ELECTROLYTES/MINERALS/METALS/VITAMINS | | |
| ELECTROLYTE/ MINERAL REPLACEMENT | | |
| CARBAGLU ORAL TABLET 200 MG | 5 | NMO |
| ISOLYTE-S INTRAVENOUS SOLUTION | 4 | NMO |
| <i>kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%, 40-5-0.9 meq/l-%-%</i> | 4 | NMO |
| <i>kcl-lactated ringers-d5w intravenous solution 20 meq/l</i> | 4 | NMO |
| KLOR-CON 10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | GC |
| KLOR-CON M10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | GC |
| KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ | 1 | GC |
| KLOR-CON M20 ORAL TABLET EXTENDED RELEASE 20 MEQ | 1 | GC |
| KLOR-CON ORAL TABLET EXTENDED RELEASE 8 MEQ | 1 | GC |
| <i>magnesium sulfate injection solution 50 %, 50 % (10ml syringe)</i> | 4 | NMO |
| NORMOSOL-M IN D5W INTRAVENOUS SOLUTION | 3 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION | 3 | NMO |
| PLASMA-LYTE A INTRAVENOUS SOLUTION | 3 | NMO |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 20 meq</i> | 1 | GC |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i> | 1 | GC |
| <i>potassium chloride er oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | GC |
| <i>potassium chloride in dextrose intravenous solution 20-5 meq/l-%</i> | 4 | NMO |
| <i>potassium chloride in nacl intravenous solution 20-0.45 meq/l-%, 20-0.9 meq/l-%, 40-0.9 meq/l-%</i> | 4 | NMO |
| <i>potassium chloride intravenous solution 10 meq/100ml, 2 meq/ml, 2 meq/ml (20 ml), 20 meq/100ml, 40 meq/100ml</i> | 4 | NMO |
| <i>potassium chloride oral solution 20 meq/15ml (10%), 40 meq/15ml (20%)</i> | 2 | |
| <i>potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg)</i> | 2 | NMO |
| <i>sodium chloride intravenous solution 0.45 %, 0.9 %, 3 %, 5 %</i> | 4 | NMO |
| <i>sodium chloride irrigation solution 0.9 %</i> | 1 | NMO; GC |
| <i>sodium fluoride oral tablet 2.2 (1 f) mg</i> | 1 | NMO; GC |
| SUPREP BOWEL PREP KIT ORAL SOLUTION 17.5-3.13-1.6 GM/177ML | 4 | NMO |
| ELECTROLYTE/MINERAL/METAL MODIFIERS | | |
| CLOVIQUE ORAL CAPSULE 250 MG | 5 | PA; NMO |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> | 5 | PA; NMO |
| <i>deferasirox oral tablet soluble 125 mg, 250 mg, 500 mg</i> | 5 | PA; NMO |
| <i>deferiprone oral tablet 500 mg</i> | 5 | NMO |
| SAMSCA ORAL TABLET 15 MG, 30 MG | 5 | PA; NMO |
| <i>tolvaptan oral tablet 15 mg, 30 mg</i> | 5 | PA; NMO |
| <i>trientine hcl oral capsule 250 mg</i> | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| ELECTROLYTES/MINERALS/METALS/VITAMINS | | |
| AMINOSYN-PF INTRAVENOUS SOLUTION 7 % | 4 | BD; NMO |
| CLINISOL SF INTRAVENOUS SOLUTION 15 % | 4 | BD; NMO |
| <i>dextrose intravenous solution 10 %, 5 %</i> | 4 | BD; NMO |
| <i>dextrose-nacl intravenous solution 10-0.2 %, 10-0.45 %, 2.5-0.45 %, 5-0.2 %, 5-0.45 %, 5-0.9 %</i> | 4 | NMO |
| DOJOLVI ORAL LIQUID 100 % | 5 | PA; NMO |
| HEPATAMINE INTRAVENOUS SOLUTION 8 % | 4 | BD; NMO |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 4 | BD; NMO |
| ISOLYTE-P IN D5W INTRAVENOUS SOLUTION | 3 | BD; NMO |
| <i>levocarnitine oral solution 1 gm/10ml</i> | 1 | BD; GC |
| <i>levocarnitine oral tablet 330 mg</i> | 4 | BD |
| NEPHRAMINE INTRAVENOUS SOLUTION 5.4 % | 4 | BD; NMO |
| NUTRILIPID INTRAVENOUS EMULSION 20 % | 4 | BD; NMO |
| PLENAMINE INTRAVENOUS SOLUTION 15 % | 4 | BD; NMO |
| PREMASOL INTRAVENOUS SOLUTION 10 % | 4 | BD; NMO |
| <i>prenatal oral tablet 27-1 mg</i> | 1 | NMO; GC |
| PROCALAMINE INTRAVENOUS SOLUTION 3 % | 4 | BD; NMO |
| PROSOL INTRAVENOUS SOLUTION 20 % | 4 | BD; NMO |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE | 4 | BD; NMO |
| TRAVASOL INTRAVENOUS SOLUTION 10 % | 4 | BD; NMO |
| TROPHAMINE INTRAVENOUS SOLUTION 10 % | 4 | BD; NMO |
| PHOSPHATE BINDERS | | |
| AURYXIA ORAL TABLET 1 GM 210 MG(Fe) | 3 | PA |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>calcium acetate (phos binder) oral capsule 667 mg</i> | 2 | |
| <i>calcium acetate (phos binder) oral tablet 667 mg</i> | 2 | |
| <i>sevelamer carbonate oral packet 0.8 gm, 2.4 gm</i> | 5 | NMO |
| <i>sevelamer carbonate oral tablet 800 mg</i> | 3 | |
| VELPHORO ORAL TABLET CHEWABLE 500 MG | 3 | |
| POTASSIUM BINDERS | | |
| LOKELMA ORAL PACKET 10 GM, 5 GM | 4 | |
| <i>sodium polystyrene sulfonate oral powder</i> | 2 | NMO |
| SPS ORAL SUSPENSION 15 GM/60ML | 3 | NMO |
| GASTROINTESTINAL AGENTS | | |
| ANTI-CONSTIPATION AGENTS | | |
| AMITIZA ORAL CAPSULE 24 MCG, 8 MCG | 3 | |
| <i>constulose oral solution 10 gm/15ml</i> | 2 | |
| <i>enulose oral solution 10 gm/15ml</i> | 2 | |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM | 1 | NMO; GC |
| GAVILYTE-G ORAL SOLUTION RECONSTITUTED 236 GM | 1 | NMO; GC |
| GAVILYTE-N WITH FLAVOR PACK ORAL SOLUTION RECONSTITUTED 420 GM | 1 | NMO; GC |
| <i>generlac oral solution 10 gm/15ml</i> | 2 | |
| <i>lactulose oral solution 10 gm/15ml</i> | 2 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | NMO |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm</i> | 1 | NMO; GC |
| <i>peg-3350/electrolytes oral solution reconstituted 236 gm</i> | 2 | NMO |
| TRILYTE ORAL SOLUTION RECONSTITUTED 420 GM | 1 | NMO; GC |
| ANTI-DIARRHEAL AGENTS | | |
| <i>alosetron hcl oral tablet 0.5 mg, 1 mg</i> | 5 | NMO |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5ml</i> | 1 | NMO; GC |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 4 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>loperamide hcl oral capsule 2 mg</i> | 1 | NMO; GC |
| ANTISPASMODICS, GASTROINTESTINAL | | |
| <i>dicyclomine hcl oral capsule 10 mg</i> | 1 | NMO; GC |
| <i>dicyclomine hcl oral solution 10 mg/5ml</i> | 2 | NMO |
| <i>dicyclomine hcl oral tablet 20 mg</i> | 1 | NMO; GC |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 2 | NMO |
| GASTROINTESTINAL AGENTS, OTHER | | |
| <i>amoxicill-clarithro-lansopraz oral</i> | 3 | NMO |
| CLENPIQ ORAL SOLUTION 10-3.5-12 MG- GM -GM/160ML | 4 | NMO |
| GATTEX SUBCUTANEOUS KIT 5 MG | 5 | PA; NMO |
| <i>metoclopramide hcl oral solution 5 mg/5ml</i> | 2 | NMO |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 1 | GC |
| PYLERA ORAL CAPSULE 140-125-125 MG | 4 | NMO |
| <i>ursodiol oral capsule 300 mg</i> | 2 | |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 2 | |
| HISTAMINE2 (H2) RECEPTOR ANTAGONISTS | | |
| <i>cimetidine hcl oral solution 300 mg/5ml</i> | 2 | |
| <i>cimetidine oral tablet 200 mg</i> | 2 | NMO |
| <i>cimetidine oral tablet 300 mg, 400 mg, 800 mg</i> | 2 | |
| <i>famotidine oral suspension reconstituted 40 mg/5ml</i> | 3 | |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 1 | GC |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 2 | |
| <i>nizatidine oral solution 15 mg/ml</i> | 2 | |
| PROTECTANTS | | |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 2 | |
| <i>sucrafate oral suspension 1 gm/10ml</i> | 4 | |
| <i>sucrafate oral tablet 1 gm</i> | 1 | GC |
| PROTON PUMP INHIBITORS | | |
| DEXILANT ORAL CAPSULE DELAYED RELEASE 30 MG, 60 MG | 3 | QL (30 EA per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|--------------------------------------|
| <i>esomeprazole magnesium oral capsule delayed release 20 mg, 40 mg</i> | 2 | |
| <i>lansoprazole oral capsule delayed release 15 mg, 30 mg</i> | 2 | |
| <i>omeprazole oral capsule delayed release 10 mg, 20 mg, 40 mg</i> | 1 | GC |
| <i>pantoprazole sodium oral tablet delayed release 20 mg, 40 mg</i> | 1 | GC |
| <i>rabeprazole sodium oral tablet delayed release 20 mg</i> | 2 | |
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | | |
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | | |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 36000 UNIT, 6000 UNIT | 3 | |
| <i>cromolyn sodium oral concentrate 100 mg/5ml</i> | 4 | |
| CYSTADANE ORAL POWDER | 5 | NMO |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG | 3 | |
| ENDARI ORAL PACKET 5 GM | 4 | PA; LA; NMO; QL (180 EA per 30 days) |
| GALAFOLD ORAL CAPSULE 123 MG | 5 | PA; LA; NMO; QL (15 EA per 30 days) |
| KUVAN ORAL PACKET 100 MG, 500 MG | 5 | PA; LA; NMO |
| KUVAN ORAL TABLET SOLUBLE 100 MG | 5 | PA; LA; NMO |
| <i>miglustat oral capsule 100 mg</i> | 5 | PA; NMO |
| <i>nitisinone oral capsule 10 mg, 2 mg, 5 mg</i> | 5 | NMO |
| ORFADIN ORAL CAPSULE 20 MG | 5 | NMO |
| ORFADIN ORAL SUSPENSION 4 MG/ML | 5 | LA; NMO |
| PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG | 5 | PA; NMO |
| <i>sapropterin dihydrochloride oral packet 100 mg, 500 mg</i> | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|------------------------------------|
| <i>sapropterin dihydrochloride oral tablet soluble 100 mg</i> | 5 | PA; NMO |
| <i>sodium phenylbutyrate oral powder 3 gm/tsp</i> | 5 | NMO |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> | 5 | NMO |
| TEGSEDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 284 MG/1.5ML | 5 | PA; LA; NMO; QL (6 ML per 28 days) |
| VYNDAMAX ORAL CAPSULE 61 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000- 79000 UNIT, 3000-14000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT | 3 | |
| GENITOURINARY AGENTS | | |
| ANTISPASMODICS, URINARY | | |
| <i>darifenacin hydrobromide er oral tablet extended release 24 hour 15 mg, 7.5 mg</i> | 2 | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HOUR 25 MG, 50 MG | 3 | |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg, 5 mg</i> | 2 | |
| <i>oxybutynin chloride oral syrup 5 mg/5ml</i> | 2 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 1 | GC |
| <i>tolterodine tartrate er oral capsule extended release 24 hour 2 mg, 4 mg</i> | 2 | |
| <i>tolterodine tartrate oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>tropium chloride er oral capsule extended release 24 hour 60 mg</i> | 2 | |
| <i>tropium chloride oral tablet 20 mg</i> | 2 | |
| BENIGN PROSTATIC HYPERTROPHY AGENTS | | |
| <i>alfuzosin hcl er oral tablet extended release 24 hour 10 mg</i> | 1 | GC |
| <i>dutasteride oral capsule 0.5 mg</i> | 2 | |
| <i>dutasteride-tamsulosin hcl oral capsule 0.5-0.4 mg</i> | 2 | |
| <i>finasteride oral tablet 5 mg</i> | 1 | GC |
| <i>silodosin oral capsule 4 mg, 8 mg</i> | 4 | |
| <i>tamsulosin hcl oral capsule 0.4 mg</i> | 1 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| GENITOURINARY AGENTS, OTHER | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | NMO |
| ELMIRON ORAL CAPSULE 100 MG | 4 | NMO |
| <i>penicillamine oral tablet 250 mg</i> | 4 | NMO |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | | |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | | |
| ALKINDI SPRINKLE ORAL CAPSULE SPRINKLE 0.5 MG | 4 | PA |
| ALKINDI SPRINKLE ORAL CAPSULE SPRINKLE 1 MG, 2 MG, 5 MG | 5 | PA; NMO |
| <i>cortisone acetate oral tablet 25 mg</i> | 3 | NMO |
| <i>dexamethasone oral elixir 0.5 mg/5ml</i> | 2 | NMO |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 1 | NMO; GC |
| <i>fludrocortisone acetate oral tablet 0.1 mg</i> | 1 | GC |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | NMO |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 2 | NMO |
| <i>methylprednisolone oral tablet therapy pack 4 mg</i> | 2 | NMO |
| <i>prednisolone oral solution 15 mg/5ml</i> | 4 | NMO |
| <i>prednisolone sodium phosphate oral solution 10 mg/5ml, 20 mg/5ml, 25 mg/5ml, 6.7 (5 base) mg/5ml</i> | 4 | NMO |
| PREDNISON INTENSOL ORAL CONCENTRATE 5 MG/ML | 4 | NMO |
| <i>prednisone oral solution 5 mg/5ml</i> | 4 | NMO |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | NMO; GC |
| <i>prednisone oral tablet therapy pack 10 mg (21), 10 mg (48), 5 mg (21), 5 mg (48)</i> | 1 | NMO; GC |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY) | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY) | | |
| <i>desmopressin ace spray refrig nasal solution 0.01 %</i> | 2 | |
| <i>desmopressin acetate oral tablet 0.1 mg, 0.2 mg</i> | 2 | |
| INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML | 5 | PA; LA; NMO |
| NOCDURNA SUBLINGUAL TABLET SUBLINGUAL 27.7 MCG, 55.3 MCG | 4 | |
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10 MG/1.5ML, 5 MG/1.5ML | 5 | PA; NMO |
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 5.8 MG | 5 | PA; NMO |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS) | | |
| ANABOLIC STEROIDS | | |
| ANADROL-50 ORAL TABLET 50 MG | 5 | NMO |
| <i>oxandrolone oral tablet 10 mg</i> | 5 | PA; NMO |
| <i>oxandrolone oral tablet 2.5 mg</i> | 4 | PA; NMO |
| ANDROGENS | | |
| ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 MG/24HR, 4 MG/24HR | 3 | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | NMO |
| <i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 2 | NMO |
| <i>testosterone enanthate intramuscular solution 200 mg/ml</i> | 4 | NMO |
| <i>testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i> | 4 | |
| <i>testosterone transdermal solution 30 mg/act</i> | 4 | |
| ESTROGENS | | |
| DIVIGEL TRANSDERMAL GEL 1 MG/GM | 4 | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | |
| <i>estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | |
| <i>estradiol vaginal cream 0.1 mg/gm</i> | 3 | |
| <i>estradiol vaginal tablet 10 mcg</i> | 4 | |
| EVAMIST TRANSDERMAL SOLUTION 1.53 MG/SPRAY | 4 | |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG, 4 MCG | 4 | |
| IMVEXXY STARTER PACK VAGINAL INSERT 10 MCG, 4 MCG | 4 | |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG | 4 | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 3 | |
| PREMARIN VAGINAL CREAM 0.625 MG/GM | 3 | |
| YUVAFEM VAGINAL TABLET 10 MCG | 4 | |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS) | | |
| ALTAVERA ORAL TABLET 0.15-30 MG-MCG | 2 | |
| <i>alyacen 1/35 oral tablet 1-35 mg-mcg</i> | 2 | |
| APRI ORAL TABLET 0.15-30 MG-MCG | 2 | |
| ARANELLE ORAL TABLET 0.5/1/0.5-35 MG-MCG | 2 | |
| AUBRA EQ ORAL TABLET 0.1-20 MG-MCG | 2 | |
| AVIANE ORAL TABLET 0.1-20 MG-MCG | 2 | |
| BALZIVA ORAL TABLET 0.4-35 MG-MCG | 2 | |
| BLISOVI 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | |
| BLISOVI FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | 2 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| CAMRESE LO ORAL TABLET 0.1-0.02 & 0.01 MG | 4 | |
| CAZIAN T ORAL TABLET 0.1/0.125/0.15 - 0.025 MG | 2 | |
| CRYSELLE-28 ORAL TABLET 0.3-30 MG-MCG | 1 | GC |
| CYCLAFEM 1/35 ORAL TABLET 1-35 MG-MCG | 2 | |
| CYCLAFEM 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 2 | |
| CYRED EQ ORAL TABLET 0.15-30 MG-MCG | 2 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i> | 2 | |
| EMOQUETTE ORAL TABLET 0.15-30 MG-MCG | 2 | |
| ENPRESSE-28 ORAL TABLET 50-30/75-40/125-30 MCG | 1 | GC |
| ENSKYCE ORAL TABLET 0.15-30 MG-MCG | 2 | |
| ESTARYLLA ORAL TABLET 0.25-35 MG-MCG | 2 | |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 2 | |
| FALMINA ORAL TABLET 0.1-20 MG-MCG | 2 | |
| FEMYNOR ORAL TABLET 0.25-35 MG-MCG | 2 | |
| FYAVOLV ORAL TABLET 0.5-2.5 MG-MCG, 1-5 MG-MCG | 4 | |
| GIANVI ORAL TABLET 3-0.02 MG | 2 | |
| HAILEY 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | |
| INTRAROSA VAGINAL INSERT 6.5 MG | 4 | PA |
| INTROVALE ORAL TABLET 0.15-0.03 MG | 2 | |
| ISIBLOOM ORAL TABLET 0.15-30 MG-MCG | 1 | GC |
| JASMIEL ORAL TABLET 3-0.02 MG | 2 | |
| JINTELI ORAL TABLET 1-5 MG-MCG | 4 | |
| JULEBER ORAL TABLET 0.15-30 MG-MCG | 2 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| JUNEL 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | |
| JUNEL 1/20 ORAL TABLET 1-20 MG-MCG | 2 | |
| JUNEL FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | GC |
| JUNEL FE 1/20 ORAL TABLET 1-20 MG-MCG | 2 | |
| JUNEL FE 24 ORAL TABLET 1-20 MG-MCG(24) | 2 | |
| KARIVA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | |
| KELNOR 1/35 ORAL TABLET 1-35 MG-MCG | 2 | |
| KELNOR 1/50 ORAL TABLET 1-50 MG-MCG | 2 | |
| KURVELO ORAL TABLET 0.15-30 MG-MCG | 2 | |
| LARIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | |
| LARIN 1/20 ORAL TABLET 1-20 MG-MCG | 2 | |
| LARIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | |
| LARIN FE 1/20 ORAL TABLET 1-20 MG-MCG | 2 | |
| LARISSIA ORAL TABLET 0.1-20 MG-MCG | 2 | |
| LEENA ORAL TABLET 0.5/1/0.5-35 MG-MCG | 2 | |
| LESSINA ORAL TABLET 0.1-20 MG-MCG | 1 | GC |
| LEVONEST ORAL TABLET 50-30/75-40/ 125-30 MCG | 2 | |
| <i>levonorgest-eth estrad 91-day oral tablet 0.1-0.02 & 0.01 mg</i> | 4 | |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-30 mg-mcg</i> | 2 | |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30 mcg</i> | 2 | |
| LEVORA 0.15/30 (28) ORAL TABLET 0.15-30 MG-MCG | 2 | |
| LORYNA ORAL TABLET 3-0.02 MG | 2 | |
| LOW-OGESTREL ORAL TABLET 0.3-30 MG-MCG | 2 | |
| LUTERA ORAL TABLET 0.1-20 MG-MCG | 2 | |
| <i>marlissa oral tablet 0.15-30 mg-mcg</i> | 2 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| MICROGESTIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | |
| MICROGESTIN 1/20 ORAL TABLET 1-20 MG-MCG | 2 | |
| MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | GC |
| MICROGESTIN FE 1/20 ORAL TABLET 1-20 MG-MCG | 2 | |
| MILI ORAL TABLET 0.25-35 MG-MCG | 2 | |
| NECON 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 2 | |
| NIKKI ORAL TABLET 3-0.02 MG | 2 | |
| <i>norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>norethindrone-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 4 | |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| NORTREL 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 2 | |
| NORTREL 1/35 (21) ORAL TABLET 1-35 MG-MCG | 2 | |
| NORTREL 1/35 (28) ORAL TABLET 1-35 MG-MCG | 2 | |
| NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 2 | |
| OCELLA ORAL TABLET 3-0.03 MG | 2 | |
| ORSYTHIA ORAL TABLET 0.1-20 MG-MCG | 2 | |
| PIMTREA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | |
| PIRMELLA 1/35 ORAL TABLET 1-35 MG-MCG | 2 | |
| PORTIA-28 ORAL TABLET 0.15-30 MG-MCG | 2 | |
| PREMPHASE ORAL TABLET 0.625-5 MG | 3 | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | |
| PREVIFEM ORAL TABLET 0.25-35 MG-MCG | 2 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| RECLIPSEN ORAL TABLET 0.15-30 MG-MCG | 2 | |
| SETLAKIN ORAL TABLET 0.15-0.03 MG | 2 | |
| SPRINTEC 28 ORAL TABLET 0.25-35 MG-MCG | 1 | GC |
| SRONYX ORAL TABLET 0.1-20 MG-MCG | 2 | |
| SYEDA ORAL TABLET 3-0.03 MG | 2 | |
| TARINA 24 FE ORAL TABLET 1-20 MG-MCG(24) | 2 | |
| TARINA FE 1/20 EQ ORAL TABLET 1-20 MG-MCG | 2 | |
| TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 2 | |
| TRI-LEGEST FE ORAL TABLET 1-20/1-30/1-35 MG-MCG | 2 | |
| TRI-LO-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | |
| TRI-LO-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | |
| TRI-MILI ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 2 | |
| TRI-PREVIFEM ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 2 | |
| TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 2 | |
| TRIVORA (28) ORAL TABLET 50-30/75-40/125-30 MCG | 2 | |
| TRI-VYLIBRA LO ORAL TABLET 0.18/0.215/0.25 MG-25 MCG | 2 | |
| TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 2 | |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025 MG | 1 | GC |
| VIENVA ORAL TABLET 0.1-20 MG-MCG | 2 | |
| VYFEMLA ORAL TABLET 0.4-35 MG-MCG | 2 | |
| VYLIBRA ORAL TABLET 0.25-35 MG-MCG | 2 | |
| ZARAH ORAL TABLET 3-0.03 MG | 2 | |
| ZOVIA 1/35E (28) ORAL TABLET 1-35 MG-MCG | 2 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| PROGESTINS | | |
| CAMILA ORAL TABLET 0.35 MG | 1 | GC |
| DEBLITANE ORAL TABLET 0.35 MG | 3 | |
| ERRIN ORAL TABLET 0.35 MG | 3 | |
| INCASSIA ORAL TABLET 0.35 MG | 3 | |
| LYZA ORAL TABLET 0.35 MG | 3 | |
| <i>medroxyprogesterone acetate intramuscular suspension 150 mg/ml</i> | 4 | NMO |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml</i> | 4 | NMO |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | GC |
| <i>megestrol acetate oral suspension 40 mg/ml</i> | 3 | NMO |
| <i>megestrol acetate oral suspension 625 mg/5ml</i> | 4 | |
| <i>megestrol acetate oral tablet 20 mg, 40 mg</i> | 1 | NMO; GC |
| NORA-BE ORAL TABLET 0.35 MG | 3 | |
| <i>norethindrone acetate oral tablet 5 mg</i> | 2 | |
| <i>norethindrone oral tablet 0.35 mg</i> | 1 | GC |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> | 2 | |
| SHAROBEL ORAL TABLET 0.35 MG | 3 | |
| SELECTIVE ESTROGEN RECEPTOR MODIFYING AGENTS | | |
| OSPHENA ORAL TABLET 60 MG | 3 | PA |
| <i>raloxifene hcl oral tablet 60 mg</i> | 2 | |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID) | | |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID) | | |
| EUTHYROX ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | GC |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| LEVO-T ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | GC |
| <i>levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | GC |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 3 | |
| <i>liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 1 | GC |
| SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 3 | |
| TIROSINT ORAL CAPSULE 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 3 | |
| UNITHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 3 | |
| HORMONAL AGENTS, SUPPRESSANT (PITUITARY) | | |
| HORMONAL AGENTS, SUPPRESSANT (PITUITARY) | | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | NMO |
| ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG | 4 | BD; NMO |
| FIRMAGON (240 MG DOSE) SUBCUTANEOUS SOLUTION RECONSTITUTED 120 MG/VIAL | 5 | BD; NMO |
| FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG | 4 | BD; NMO |
| ISTURISA ORAL TABLET 1 MG, 10 MG, 5 MG | 5 | PA; NMO |
| <i>leuprolide acetate injection kit 1 mg/0.2ml</i> | 4 | PA; NMO |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG, 7.5 MG | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|------------------------------------|
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG, 22.5 MG | 5 | PA; NMO |
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30 MG | 5 | PA; NMO |
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45 MG | 5 | PA; NMO |
| <i>octreotide acetate injection solution 100 mcg/ml, 200 mcg/ml, 50 mcg/ml</i> | 4 | PA |
| <i>octreotide acetate injection solution 1000 mcg/ml, 500 mcg/ml</i> | 5 | PA; NMO |
| ORLISSA ORAL TABLET 150 MG, 200 MG | 4 | PA; NMO |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML, 0.6 MG/ML, 0.9 MG/ML | 5 | PA; NMO; QL (60 ML per 30 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 120 MG/0.5ML, 60 MG/0.2ML, 90 MG/0.3ML | 5 | PA; NMO |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; LA; NMO |
| SYNAREL NASAL SOLUTION 2 MG/ML | 5 | NMO |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG | 5 | BD; NMO |
| HORMONAL AGENTS, SUPPRESSANT (THYROID) | | |
| ANTITHYROID AGENTS | | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | GC |
| <i>propylthiouracil oral tablet 50 mg</i> | 1 | GC |
| IMMUNOLOGICAL AGENTS | | |
| ANGIOEDEMA AGENTS | | |
| CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT | 5 | PA; NMO |
| FIRAZYR SUBCUTANEOUS SOLUTION 30 MG/3ML | 5 | PA; NMO |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2ML | 5 | PA; LA; NMO |
| IMMUNOGLOBULINS | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| GAMMAGARD INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML | 5 | PA; NMO |
| GAMMAGARD S/D LESS IGA INTRAVENOUS SOLUTION RECONSTITUTED 10 GM, 5 GM | 5 | PA; NMO |
| GAMUNEX-C INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML | 5 | PA; NMO |
| OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML | 5 | PA; NMO |
| PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML | 5 | PA; NMO |
| IMMUNOLOGICAL AGENTS, OTHER | | |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220 MG | 5 | PA; NMO |
| COSENTYX (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 5 | PA; NMO |
| COSENTYX SENSOREADY (300 MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML | 5 | PA; NMO |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 MG/2ML | 5 | PA; NMO |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML | 5 | PA; NMO |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 2 | |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML | 5 | PA; NMO |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML | 5 | PA; NMO |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5 | PA; NMO |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 11 MG, 22 MG | 5 | PA; NMO |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG | 5 | PA; NMO |
| IMMUNOSTIMULANTS | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000 UNIT/0.5ML | 5 | PA; LA; NMO |
| INTRON A INJECTION SOLUTION 10000000 UNIT/ML, 6000000 UNIT/ML | 5 | BD; NMO |
| INTRON A INJECTION SOLUTION RECONSTITUTED 10000000 UNIT, 18000000 UNIT, 50000000 UNIT | 5 | BD; NMO |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/0.5ML, 180 MCG/ML | 5 | PA; NMO |
| IMMUNOSUPPRESSANTS | | |
| <i>azathioprine oral tablet 50 mg</i> | 1 | BD; GC |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML | 5 | NMO |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML | 5 | NMO |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | BD |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | 3 | BD |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | 3 | BD |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML | 5 | PA; NMO |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML | 5 | PA; NMO |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 MG/ML | 5 | PA; NMO |
| ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED 25 MG | 5 | PA; NMO |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML | 5 | PA; NMO |
| ENSPRYNG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML | 5 | PA; NMO |
| ENVARUSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG | 4 | BD |
| <i>everolimus oral tablet 0.25 mg</i> | 4 | BD |
| <i>everolimus oral tablet 0.5 mg, 0.75 mg</i> | 5 | BD; NMO |
| GENGRAF ORAL CAPSULE 100 MG, 25 MG | 3 | BD |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| GENGRAF ORAL SOLUTION 100 MG/ML | 3 | BD |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML | 5 | PA; NMO |
| HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML | 5 | PA; NMO |
| HUMIRA PEN-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML | 5 | PA; NMO |
| HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML | 5 | PA; NMO |
| HUMIRA PEN-PSOR/UEIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML & 40MG/0.4ML | 5 | PA; NMO |
| HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 10 MG/0.2ML, 20 MG/0.2ML, 20 MG/0.4ML, 40 MG/0.4ML, 40 MG/0.8ML | 5 | PA; NMO |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | NMO |
| <i>methotrexate oral tablet 2.5 mg</i> | 2 | BD; NMO |
| <i>methotrexate sodium (pf) injection solution 50 mg/2ml</i> | 3 | BD; NMO |
| <i>methotrexate sodium injection solution 50 mg/2ml</i> | 3 | BD; NMO |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 2 | BD |
| <i>mycophenolate mofetil oral suspension reconstituted 200 mg/ml</i> | 5 | BD; NMO |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 2 | BD |
| <i>mycophenolate sodium oral tablet delayed release 180 mg, 360 mg</i> | 2 | BD |
| PROGRAF ORAL PACKET 0.2 MG, 1 MG | 4 | BD |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML | 3 | BD |
| <i>sirolimus oral solution 1 mg/ml</i> | 5 | BD; NMO |
| <i>sirolimus oral tablet 0.5 mg, 1 mg</i> | 4 | BD |
| <i>sirolimus oral tablet 2 mg</i> | 5 | BD; NMO |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg</i> | 2 | BD |
| <i>tacrolimus oral capsule 5 mg</i> | 4 | BD |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG | 4 | BD; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| ZORTRESS ORAL TABLET 1 MG | 5 | BD; NMO |
| VACCINES | | |
| ACTHIB INTRAMUSCULAR SOLUTION RECONSTITUTED | 6 | NMO |
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 (PREFILLED SYRINGE), 5-2-15.5 LF-MCG/0.5 | 6 | NMO |
| <i>bcg vaccine injection injectable</i> | 6 | GC; NMO |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 6 | NMO |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 , 5-2.5-18.5 (0.5ML SYRINGE) | 6 | NMO |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5 | 6 | NMO |
| <i>diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml</i> | 6 | BD; GC; NMO |
| ENGERIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML | 6 | BD; NMO |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION | 6 | NMO |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 6 | NMO |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 1440 EL U/ML 1 ML, 720 EL U/0.5ML | 6 | NMO |
| HIBERIX INJECTION SOLUTION RECONSTITUTED 10 MCG | 6 | NMO |
| IMOVAX RABIES INTRAMUSCULAR INJECTABLE 2.5 UNIT/ML | 6 | BD; NMO |
| INFANRIX INTRAMUSCULAR SUSPENSION 25-58-10 | 6 | NMO |
| IPOL INJECTION INJECTABLE | 6 | NMO |
| IXIARO INTRAMUSCULAR SUSPENSION | 6 | NMO |
| KINRIX INTRAMUSCULAR SUSPENSION , INJECTION 0.5 ML | 6 | NMO |
| MENACTRA INTRAMUSCULAR INJECTABLE | 6 | NMO |
| MENQUADFI INTRAMUSCULAR INJECTABLE | 6 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED | 6 | NMO |
| M-M-R II INJECTION SOLUTION RECONSTITUTED | 6 | NMO |
| PEDIARIX INTRAMUSCULAR SUSPENSION | 6 | NMO |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION 7.5 MCG/0.5ML | 6 | NMO |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED | 6 | NMO |
| QUADRACEL INTRAMUSCULAR SUSPENSION | 6 | NMO |
| RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED | 6 | BD; NMO |
| RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 10 MCG/ML (1ML SYRINGE), 40 MCG/ML, 5 MCG/0.5ML | 6 | BD; NMO |
| ROTARIX ORAL SUSPENSION RECONSTITUTED | 6 | NMO |
| ROTATEQ ORAL SOLUTION | 6 | NMO |
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML | 6 | NMO |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML | 6 | BD; NMO |
| TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU | 6 | BD; NMO |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 6 | NMO |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML | 6 | NMO |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5ML, 25 MCG/0.5ML (0.5ML SYRINGE) | 6 | NMO |
| VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 25 UNIT/0.5ML 0.5 ML, 50 UNIT/ML, 50 UNIT/ML 1 ML | 6 | NMO |
| VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML | 6 | NMO |
| VARIZIG INTRAMUSCULAR SOLUTION 125 UNIT/1.2ML | 5 | NMO |
| YF-VAX SUBCUTANEOUS INJECTABLE | 6 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------------|
| INFLAMMATORY BOWEL DISEASE AGENTS | | |
| AMINOSALICYLATES | | |
| <i>balsalazide disodium oral capsule 750 mg</i> | 2 | NMO |
| LIALDA ORAL TABLET DELAYED RELEASE 1.2 GM | 3 | |
| <i>mesalamine er oral capsule extended release 24 hour 0.375 gm</i> | 3 | |
| <i>mesalamine oral capsule delayed release 400 mg</i> | 4 | |
| <i>mesalamine oral tablet delayed release 800 mg</i> | 4 | NMO |
| <i>mesalamine rectal enema 4 gm</i> | 4 | NMO |
| <i>sulfasalazine oral tablet 500 mg</i> | 1 | GC |
| <i>sulfasalazine oral tablet delayed release 500 mg</i> | 1 | GC |
| GLUCOCORTICOIDS | | |
| <i>budesonide er oral tablet extended release 24 hour 9 mg</i> | 4 | NMO |
| <i>budesonide oral capsule delayed release particles 3 mg</i> | 4 | NMO |
| <i>hydrocortisone rectal enema 100 mg/60ml</i> | 4 | NMO |
| METABOLIC BONE DISEASE AGENTS | | |
| METABOLIC BONE DISEASE AGENTS | | |
| <i>alendronate sodium oral tablet 10 mg, 35 mg, 70 mg</i> | 1 | GC |
| <i>calcitonin (salmon) nasal solution 200 unit/act</i> | 2 | BD |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 1 | GC |
| <i>calcitriol oral solution 1 mcg/ml</i> | 2 | |
| <i>cinacalcet hcl oral tablet 30 mg</i> | 3 | BD; QL (120 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 60 mg</i> | 5 | BD; NMO; QL (150 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 90 mg</i> | 5 | BD; NMO; QL (120 EA per 30 days) |
| <i>ibandronate sodium oral tablet 150 mg</i> | 2 | |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG, 25 MCG, 50 MCG, 75 MCG | 5 | PA; NMO |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | 4 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60 MG/ML | 4 | NMO |
| <i>risedronate sodium oral tablet 150 mg, 35 mg, 35 mg (12 pack), 35 mg (4 pack), 5 mg</i> | 4 | |
| <i>risedronate sodium oral tablet 30 mg</i> | 4 | NMO |
| <i>risedronate sodium oral tablet delayed release 35 mg</i> | 4 | |
| <i>teriparatide (recombinant) subcutaneous solution pen-injector 620 mcg/2.48ml</i> | 5 | PA; NMO |
| TYMLOS SUBCUTANEOUS SOLUTION PEN-INJECTOR 3120 MCG/1.56ML | 5 | PA; NMO |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7ML | 5 | PA; NMO |
| OPHTHALMIC AGENTS | | |
| OPHTHALMIC AGENTS, OTHER | | |
| <i>atropine sulfate ophthalmic solution 1 %</i> | 2 | |
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1 %</i> | 2 | NMO |
| CYSTARAN OPHTHALMIC SOLUTION 0.44 % | 5 | PA; NMO |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | 1 | NMO; GC |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | 3 | NMO |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 2 | NMO |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i> | 3 | NMO |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1 unit/ml-%</i> | 1 | NMO; GC |
| <i>proparacaine hcl ophthalmic solution 0.5 %</i> | 2 | NMO |
| RESTASIS OPHTHALMIC EMULSION 0.05 % | 3 | |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23 %</i> | 2 | NMO |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %</i> | 2 | NMO |
| OPHTHALMIC ANTI-ALLERGY AGENTS | | |
| <i>azelastine hcl ophthalmic solution 0.05 %</i> | 2 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>cromolyn sodium ophthalmic solution 4 %</i> | 2 | NMO |
| <i>olopatadine hcl ophthalmic solution 0.1 %, 0.2 %</i> | 3 | NMO |
| PAZEO OPHTHALMIC SOLUTION 0.7 % | 4 | NMO |
| OPHTHALMIC ANTI-INFECTIVES | | |
| AZASITE OPHTHALMIC SOLUTION 1 % | 4 | NMO |
| <i>bacitracin ophthalmic ointment 500 unit/gm</i> | 2 | NMO |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i> | 2 | NMO |
| <i>erythromycin ophthalmic ointment 5 mg/gm</i> | 1 | NMO; GC |
| <i>gatifloxacin ophthalmic solution 0.5 %</i> | 2 | NMO |
| GENTAK OPHTHALMIC OINTMENT 0.3 % | 2 | NMO |
| <i>gentamicin sulfate ophthalmic solution 0.3 %</i> | 2 | NMO |
| <i>levofloxacin ophthalmic solution 0.5 %</i> | 3 | NMO |
| MOXEZA OPHTHALMIC SOLUTION 0.5 % | 3 | NMO |
| <i>moxifloxacin hcl ophthalmic solution 0.5 %</i> | 3 | NMO |
| NATACYN OPHTHALMIC SUSPENSION 5 % | 4 | NMO |
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 3 | NMO |
| <i>ofloxacin ophthalmic solution 0.3 %</i> | 2 | NMO |
| <i>sulfacetamide sodium ophthalmic solution 10 %</i> | 2 | NMO |
| <i>tobramycin ophthalmic solution 0.3 %</i> | 2 | NMO |
| OPHTHALMIC ANTI-INFLAMMATORIES | | |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09 %</i> | 2 | NMO |
| BROMSITE OPHTHALMIC SOLUTION 0.075 % | 4 | NMO |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1 %</i> | 2 | NMO |
| <i>diclofenac sodium ophthalmic solution 0.1 %</i> | 2 | NMO |
| DUREZOL OPHTHALMIC EMULSION 0.05 % | 3 | NMO |
| <i>fluorometholone ophthalmic suspension 0.1 %</i> | 2 | NMO |
| <i>flurbiprofen sodium ophthalmic solution 0.03 %</i> | 2 | NMO |
| ILEVRO OPHTHALMIC SUSPENSION 0.3 % | 3 | NMO |
| <i>ketorolac tromethamine ophthalmic solution 0.4 %, 0.5 %</i> | 2 | NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| <i>loteprednol etabonate ophthalmic suspension 0.5 %</i> | 4 | NMO |
| <i>prednisolone acetate ophthalmic suspension 1 %</i> | 2 | NMO |
| <i>prednisolone sodium phosphate ophthalmic solution 1 %</i> | 2 | NMO |
| OPHTHALMIC BETA-ADRENERGIC BLOCKING AGENTS | | |
| <i>betaxolol hcl ophthalmic solution 0.5 %</i> | 2 | |
| <i>carteolol hcl ophthalmic solution 1 %</i> | 2 | |
| <i>levobunolol hcl ophthalmic solution 0.5 %</i> | 2 | |
| <i>timolol maleate ophthalmic gel forming solution 0.25 %, 0.5 %</i> | 2 | |
| <i>timolol maleate ophthalmic solution 0.25 %, 0.5 %</i> | 1 | GC |
| OPHTHALMIC INTRAOCULAR PRESSURE LOWERING AGENTS, OTHER | | |
| <i>acetazolamide er oral capsule extended release 12 hour 500 mg</i> | 6 | GC |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 6 | GC |
| ALPHAGAN P OPHTHALMIC SOLUTION 0.1 % | 3 | |
| AZOPT OPHTHALMIC SUSPENSION 1 % | 3 | |
| <i>brimonidine tartrate ophthalmic solution 0.15 %, 0.2 %</i> | 2 | |
| COMBIGAN OPHTHALMIC SOLUTION 0.2-0.5 % | 4 | |
| <i>dorzolamide hcl ophthalmic solution 2 %</i> | 1 | GC |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 22.3-6.8 mg/ml</i> | 2 | |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5 %</i> | 2 | |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 6 | GC |
| PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION RECONSTITUTED 0.125 % | 4 | |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i> | 2 | |
| ROCKLATAN OPHTHALMIC SOLUTION 0.02-0.005 % | 4 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| SIMBRINZA OPHTHALMIC SUSPENSION 1-0.2 % | 4 | |
| OPHTHALMIC PROSTAGLANDIN AND PROSTAMIDE ANALOGS | | |
| <i>latanoprost ophthalmic solution 0.005 %</i> | 1 | GC |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 % | 3 | |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02 % | 4 | |
| <i>travoprost (bak free) ophthalmic solution 0.004 %</i> | 3 | |
| OTIC AGENTS | | |
| OTIC AGENTS | | |
| <i>acetic acid otic solution 2 %</i> | 2 | NMO |
| CIPRODEX OTIC SUSPENSION 0.3-0.1 % | 4 | NMO |
| <i>ciprofloxacin hcl otic solution 0.2 %</i> | 4 | NMO |
| <i>ciprofloxacin-fluocinolone pf otic solution 0.3-0.025 %</i> | 4 | NMO |
| <i>fluocinolone acetonide otic oil 0.01 %</i> | 4 | NMO |
| <i>hydrocortisone-acetic acid otic solution 1-2 %</i> | 4 | NMO |
| <i>neomycin-polymyxin-hc otic solution 1 %</i> | 2 | NMO |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | 3 | NMO |
| <i>ofloxacin otic solution 0.3 %</i> | 4 | NMO |
| RESPIRATORY TRACT/ PULMONARY AGENTS | | |
| ANTI-HISTAMINES | | |
| <i>azelastine hcl nasal solution 0.1 %, 0.15 %</i> | 2 | NMO |
| <i>cetirizine hcl oral solution 1 mg/ml</i> | 2 | NMO |
| <i>clemastine fumarate oral tablet 2.68 mg</i> | 1 | NMO; GC |
| <i>cyproheptadine hcl oral syrup 2 mg/5ml</i> | 4 | NMO |
| <i>cyproheptadine hcl oral tablet 4 mg</i> | 4 | NMO |
| <i>levocetirizine dihydrochloride oral solution 2.5 mg/5ml</i> | 3 | NMO |
| <i>levocetirizine dihydrochloride oral tablet 5 mg</i> | 1 | NMO; GC |
| ANTI-INFLAMMATORIES, INHALED CORTICOSTEROIDS | | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|-----------------------------|
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT | 3 | |
| ASMANEX (120 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/INH | 3 | |
| ASMANEX (30 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 110 MCG/INH, 220 MCG/INH | 3 | |
| ASMANEX (60 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/INH | 3 | |
| ASMANEX HFA INHALATION AEROSOL 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT | 3 | |
| <i>budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml</i> | 4 | BD |
| FLOVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/BLIST, 250 MCG/BLIST, 50 MCG/BLIST | 3 | |
| FLOVENT HFA INHALATION AEROSOL 110 MCG/ACT, 220 MCG/ACT, 44 MCG/ACT | 3 | |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i> | 2 | NMO |
| <i>fluticasone propionate nasal suspension 50 mcg/act</i> | 2 | NMO |
| <i>mometasone furoate nasal suspension 50 mcg/act</i> | 2 | NMO; QL (34 GM per 30 days) |
| ANTILEUKOTRIENES | | |
| <i>montelukast sodium oral packet 4 mg</i> | 2 | |
| <i>montelukast sodium oral tablet 10 mg</i> | 1 | GC |
| <i>montelukast sodium oral tablet chewable 4 mg, 5 mg</i> | 2 | |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>zileuton er oral tablet extended release 12 hour 600 mg</i> | 5 | NMO |
| ZYFLO ORAL TABLET 600 MG | 5 | NMO |
| BRONCHODILATORS, ANTICHOLINERGIC | | |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | BD |
| <i>ipratropium bromide nasal solution 0.03 %, 0.06 %</i> | 2 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| SPIRIVA HANDIHALER INHALATION CAPSULE 18 MCG | 3 | |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT | 3 | |
| BRONCHODILATORS, SYMPATHOMIMETIC | | |
| <i>albuterol sulfate er oral tablet extended release 12 hour 4 mg, 8 mg</i> | 4 | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act</i> | 2 | |
| <i>albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml</i> | 2 | BD |
| <i>albuterol sulfate oral syrup 2 mg/5ml</i> | 4 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 2 | |
| <i>epinephrine injection solution 0.3 mg/0.3ml</i> | 3 | NMO |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.15ml, 0.15 mg/0.3ml, 0.3 mg/0.3ml</i> | 3 | NMO |
| <i>levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/0.5ml, 1.25 mg/3ml</i> | 4 | BD |
| <i>metaproterenol sulfate oral syrup 10 mg/5ml</i> | 4 | |
| PROAIR HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT | 3 | |
| PROAIR RESPICLICK INHALATION AEROSOL POWDER BREATH ACTIVATED 108 (90 BASE) MCG/ACT | 3 | |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/DOSE | 3 | |
| SYMJEPI INJECTION SOLUTION PREFILLED SYRINGE 0.15 MG/0.3ML, 0.3 MG/0.3ML | 3 | NMO |
| <i>terbutaline sulfate oral tablet 2.5 mg, 5 mg</i> | 4 | |
| CYSTIC FIBROSIS AGENTS | | |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG | 5 | PA; NMO |
| KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|----------------------------|
| KALYDECO ORAL TABLET 150 MG | 5 | PA; NMO |
| ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG | 5 | PA; LA; NMO |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; NMO |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 5 | BD; NMO |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150 MG, 50-75 & 75 MG | 5 | PA; LA; NMO |
| TOBI PODHALER INHALATION CAPSULE 28 MG | 5 | NMO |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i> | 5 | BD; NMO |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG | 5 | PA; NMO |
| PHOSPHODIESTERASE INHIBITORS, AIRWAYS DISEASE | | |
| DALIRESP ORAL TABLET 250 MCG, 500 MCG | 3 | QL (30 EA per 30 days) |
| <i>theophylline er oral tablet extended release 12 hour 300 mg</i> | 2 | |
| <i>theophylline er oral tablet extended release 24 hour 400 mg, 600 mg</i> | 2 | |
| PULMONARY ANTIHYPERTENSIVES | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 | PA; NMO |
| ALYQ ORAL TABLET 20 MG | 5 | PA; NMO |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | 5 | PA; NMO |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | 5 | PA; NMO |
| OPSUMIT ORAL TABLET 10 MG | 5 | PA; NMO |
| <i>sildenafil citrate oral tablet 20 mg</i> | 2 | PA; QL (90 EA per 30 days) |
| UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 5 | PA; LA; NMO |
| UPTRAVI ORAL TABLET THERAPY PACK 200 & 800 MCG | 5 | PA; LA; NMO |
| PULMONARY FIBROSIS AGENTS | | |
| ESBRIET ORAL CAPSULE 267 MG | 5 | PA; NMO |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|---|-------------|----------------------------|
| ESBRIET ORAL TABLET 267 MG, 801 MG | 5 | PA; NMO |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; NMO |
| RESPIRATORY TRACT AGENTS, OTHER | | |
| <i>acetylcysteine inhalation solution 10 %, 20 %</i> | 2 | BD; NMO |
| ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE | 3 | |
| ADVAIR HFA INHALATION AEROSOL 115-21 MCG/ACT, 230-21 MCG/ACT, 45-21 MCG/ACT | 3 | |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/INH | 3 | |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/INH, 200-25 MCG/INH | 3 | |
| <i>budesonide-formoterol fumarate inhalation aerosol 160-4.5 mcg/act, 80-4.5 mcg/act</i> | 3 | |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT | 4 | |
| <i>cromolyn sodium inhalation nebulization solution 20 mg/2ml</i> | 3 | BD |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/dose, 113-14 mcg/act, 232-14 mcg/act, 250-50 mcg/dose, 500-50 mcg/dose, 55-14 mcg/act</i> | 3 | |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | 1 | BD; GC |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML | 5 | PA; NMO |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 5 | PA; NMO |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100 MG | 5 | PA; NMO |
| SYMBICORT INHALATION AEROSOL 160-4.5 MCG/ACT, 80-4.5 MCG/ACT | 3 | |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/INH, 200-62.5-25 MCG/INH | 3 | |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| Drug Name | Tier | Requirements/Limits |
|--|-------------|--------------------------------------|
| SKELETAL MUSCLE RELAXANTS | | |
| SKELETAL MUSCLE RELAXANTS | | |
| <i>chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg</i> | 4 | PA; NMO; HR |
| <i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg</i> | 4 | PA; NMO; HR |
| <i>metaxalone oral tablet 800 mg</i> | 4 | NMO |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 4 | PA; NMO; HR |
| SLEEP DISORDER AGENTS | | |
| SLEEP PROMOTING AGENTS | | |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 4 | NMO |
| <i>flurazepam hcl oral capsule 15 mg</i> | 3 | NMO; QL (60 EA per 30 days) |
| <i>flurazepam hcl oral capsule 30 mg</i> | 3 | NMO; QL (30 EA per 30 days) |
| HETLIOZ ORAL CAPSULE 20 MG | 5 | PA; NMO; QL (30 EA per 30 days) |
| <i>temazepam oral capsule 15 mg, 22.5 mg, 30 mg</i> | 3 | NMO; QL (30 EA per 30 days) |
| <i>temazepam oral capsule 7.5 mg</i> | 3 | NMO; QL (120 EA per 30 days) |
| <i>zaleplon oral capsule 10 mg</i> | 2 | NMO; QL (60 EA per 30 days) |
| <i>zaleplon oral capsule 5 mg</i> | 2 | NMO; QL (30 EA per 30 days) |
| <i>zolpidem tartrate oral tablet 10 mg, 5 mg</i> | 2 | NMO; QL (30 EA per 30 days) |
| WAKEFULNESS PROMOTING AGENTS | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| <i>modafinil oral tablet 100 mg, 200 mg</i> | 3 | PA; QL (30 EA per 30 days) |
| SUNOSI ORAL TABLET 150 MG, 75 MG | 4 | PA; QL (30 EA per 30 days) |
| XYREM ORAL SOLUTION 500 MG/ML | 5 | PA; LA; NMO; QL (540 ML per 30 days) |

You can find information on what the symbols and abbreviations on this table mean by going to page 1 of the introduction. Formulary ID: 21526, Ver. 6 Last Updated 01/24/2021 Effective Date: 02/01/2021

| | | | | | |
|---------------------------------|--------|-----------------------------------|-------------------|----------------------------------|--------|
| BELSOMRA | 90 | bupropion hcl er (smoking det) 5 | ceftazidime | 8 | |
| benazepril hcl | 45 | bupropion hcl er (sr) | 15 | ceftriaxone sodium | 8 |
| benazepril-hydrochlorothiazide | | bupropion hcl er (xl)..... | 15 | cefuroxime axetil | 8 |
| | 49 | buspirone hcl | 38 | cefuroxime sodium | 8 |
| BENLYSTA | 77 | butalbital-apap-caffeine | 2 | celecoxib | 2 |
| benzoyl peroxide-erythromycin | | butalbital-aspirin-caffeine | 2 | CELONTIN | 13 |
| | 55 | butorphanol tartrate | 3 | cephalexin..... | 8 |
| benztropine mesylate..... | 30 | BYSTOLIC | 47 | cetirizine hcl | 85 |
| BESIVANCE | 10 | C | | cevimeline hcl..... | 55 |
| betamethasone dipropionate...56 | | cabergoline | 74 | CHANTIX | 5 |
| betamethasone dipropionate aug | | CABLIVI..... | 44 | CHANTIX CONTINUING | |
| | 56 | CABOMETYX..... | 25 | MONTH PAK | 5 |
| betamethasone valerate | 56 | calcipotriene | 58 | CHANTIX STARTING | |
| BETASERON | 55 | calcitonin (salmon)..... | 81 | MONTH PAK | 5 |
| betaxolol hcl | 47, 84 | calcitriol..... | 58, 81 | chlordiazepoxide hcl..... | 39 |
| bethanechol chloride | 66 | calcium acetate (phos binder).62 | | chlorhexidine gluconate..... | 55 |
| bexarotene | 29 | CALQUENCE..... | 25 | chloroquine phosphate..... | 29 |
| BEXSERO..... | 79 | CAMILA | 73 | chlorpromazine hcl | 31 |
| bicalutamide | 22 | CAMRESE LO..... | 69 | chlorthalidone | 51 |
| BICILLIN L-A | 9 | candesartan cilexetil | 45 | chlorzoxazone..... | 90 |
| BIDIL | 49 | candesartan cilexetil-hctz | 49 | cholestyramine..... | 52 |
| BIKTARVY | 35 | CAPLYTA..... | 32 | cholestyramine light | 52 |
| bisoprolol fumarate | 47 | CAPRELSA..... | 25 | ciclopirox | 59 |
| bisoprolol-hydrochlorothiazide | | captopril..... | 46 | ciclopirox olamine | 19 |
| | 49 | captopril-hydrochlorothiazide | 49 | cilostazol..... | 45 |
| BLISOVI 24 FE | 68 | CARBAGLU | 59 | CIMDUO | 36 |
| BLISOVI FE 1.5/30 | 68 | carbamazepine | 14 | cimetidine | 63 |
| BOOSTRIX..... | 79 | carbamazepine er | 14 | cimetidine hcl | 63 |
| bosentan..... | 88 | carbidopa-levodopa | 30 | cinacalcet hcl | 81 |
| BOSULIF | 25 | carbidopa-levodopa er | 30 | CINRYZE..... | 75 |
| BRAFTOVI..... | 25 | carbidopa-levodopa-entacapone | | CIPRODEX | 85 |
| BREO ELLIPTA | 89 | | 30 | ciprofloxacin hcl | 11, 85 |
| briellyn | 68 | CAROSPIR | 51 | ciprofloxacin in d5w..... | 11 |
| BRILINTA | 44 | carteolol hcl | 84 | ciprofloxacin-fluocinolone pf.85 | |
| brimonidine tartrate | 84 | CARTIA XT | 48 | cialopram hydrobromide | 16 |
| BRIVIACT | 12 | carvedilol | 47 | CLARAVIS | 55 |
| bromfenac sodium (once-daily) | | carvedilol phosphate er..... | 47 | clarithromycin..... | 10 |
| | 83 | caspofungin acetate | 19 | clarithromycin er | 10 |
| bromocriptine mesylate | 30 | CAYSTON | 87 | clemastine fumarate..... | 85 |
| BROMSITE..... | 83 | CAZANT | 69 | CLENPIQ | 63 |
| BRUKINSA | 25 | cefaclor | 7 | clindamycin hcl | 6 |
| budesonide..... | 81, 86 | cefadroxil..... | 7 | clindamycin palmitate hcl..... | 6 |
| budesonide er..... | 81 | cefazolin sodium..... | 7 | clindamycin phosphate | 6, 59 |
| budesonide-formoterol fumarate | | cefdinir..... | 7 | clindamycin phosphate in d5w .6 | |
| | 89 | cefepime hcl | 8 | CLINISOL SF | 61 |
| bumetanide | 51 | cefexime | 8 | clobazam..... | 13 |
| buprenorphine hcl..... | 5 | cefotetan disodium | 8 | clobetasol propionate..... | 56 |
| buprenorphine hcl-naloxone hcl | | cefoxitin sodium | 8 | clobetasol propionate emulsion | |
| | 5 | cefpodoxime proxetil..... | 8 | | 56 |
| bupropion hcl..... | 15 | cefprozil..... | 8 | clomipramine hcl | 17 |

| | | | | | |
|--|------------|--|--------|---|----|
| clonazepam..... | 39 | CYRED EQ..... | 69 | digoxin..... | 49 |
| clonidine..... | 45 | CYSTADANE..... | 64 | dihydroergotamine mesylate .. | 20 |
| clonidine hcl..... | 45 | CYSTAGON..... | 64 | DILANTIN..... | 14 |
| clopidogrel bisulfate..... | 45 | CYSTARAN..... | 82 | diltiazem hcl..... | 48 |
| clorazepate dipotassium..... | 39 | D | | diltiazem hcl er..... | 48 |
| clotrimazole..... | 19 | dalfampridine er..... | 55 | diltiazem hcl er beads..... | 48 |
| clotrimazole-betamethasone... | 58 | DALIRESP..... | 88 | diltiazem hcl er coated beads.. | 48 |
| CLOVIQUE..... | 60 | danazol..... | 67 | dilt-xr..... | 48 |
| clozapine..... | 33, 34 | dapsone..... | 21 | dimethyl fumarate..... | 55 |
| COARTEM..... | 29 | DAPTACEL..... | 79 | diphenoxylate-atropine..... | 62 |
| codeine sulfate..... | 3 | daptomycin..... | 6 | diphtheria-tetanus toxoids dt .. | 79 |
| colchicine..... | 20 | darifenacin hydrobromide er .. | 65 | dipyridamole..... | 45 |
| colchicine-probenecid..... | 20 | DAURISMO..... | 25 | disopyramide phosphate..... | 46 |
| colestipol hcl..... | 52 | DEBLITANE..... | 73 | disulfiram..... | 4 |
| colistimethate sodium (cba)..... | 6 | deferasirox..... | 60 | DIURIL..... | 51 |
| COMBIGAN..... | 84 | deferiprone..... | 60 | divalproex sodium..... | 39 |
| COMBIVENT RESPIMAT... .. | 89 | DELSTRIGO..... | 36 | divalproex sodium er..... | 39 |
| COMETRIQ (100 MG DAILY DOSE)..... | 25 | DEMSEER..... | 49 | DIVIGEL..... | 67 |
| COMETRIQ (140 MG DAILY DOSE)..... | 25 | DESCOVY..... | 36 | dofetilide..... | 46 |
| COMETRIQ (60 MG DAILY DOSE)..... | 25 | desipramine hcl..... | 17 | DOJOLVI..... | 61 |
| COMFORT ASSIST INSULIN SYRINGE..... | 42 | desmopressin ace spray refrig | 67 | donepezil hcl..... | 15 |
| COMPLERA..... | 35 | desmopressin acetate..... | 67 | dorzolamide hcl..... | 84 |
| COMPRO..... | 18 | desogestrel-ethinyl estradiol... | 69 | dorzolamide hcl-timolol mal .. | 84 |
| constulose..... | 62 | desonide..... | 56, 57 | dorzolamide hcl-timolol mal pf | 84 |
| COPAXONE..... | 55 | desoximetasone..... | 57 | DOVATO..... | 35 |
| COPIKTRA..... | 25 | desvenlafaxine er..... | 16 | doxazosin mesylate..... | 45 |
| CORLANOR..... | 49 | desvenlafaxine succinate er ... | 16 | doxepin hcl..... | 17 |
| cortisone acetate..... | 66 | dexamethasone..... | 66 | DOXY 100..... | 11 |
| COSENTYX (300 MG DOSE) | 76 | dexamethasone sodium phosphate..... | 83 | doxycycline hyclate..... | 11 |
| COSENTYX SENSOREADY (300 MG)..... | 76 | DEXILANT..... | 63 | doxycycline monohydrate..... | 11 |
| COTELLIC..... | 25 | dextroamphetamine sulfate..... | 53 | DRIZALMA SPRINKLE..... | 16 |
| CREON..... | 64 | dextrose..... | 61 | dronabinol..... | 18 |
| CRIXIVAN..... | 37 | dextrose-nacl..... | 61 | drosiprenone-ethinyl estradiol | 69 |
| cromolyn sodium..... | 64, 83, 89 | DIACOMIT..... | 12 | DROXIA..... | 23 |
| CRYSSELLE-28..... | 69 | DIASTAT ACUDIAL..... | 13 | duloxetine hcl..... | 16 |
| cvs gauze sterile..... | 42 | DIASTAT PEDIATRIC..... | 13 | DUPIXENT..... | 76 |
| CYCLAFEM 1/35..... | 69 | diazepam..... | 13, 39 | DUREZOL..... | 83 |
| CYCLAFEM 7/7/7..... | 69 | diazoxide..... | 41 | dutasteride..... | 65 |
| cyclobenzaprine hcl..... | 90 | diclofenac potassium..... | 2 | dutasteride-tamsulosin hcl..... | 65 |
| cyclophosphamide..... | 22 | diclofenac sodium..... | 2, 83 | DUTOPROL..... | 49 |
| CYCLOSET..... | 40 | diclofenac sodium er..... | 2 | E | |
| cyclosporine..... | 77 | diclofenac-misoprostol..... | 2 | econazole nitrate..... | 19 |
| cyclosporine modified..... | 77 | dicloxacillin sodium..... | 9 | EDARBI..... | 45 |
| cyproheptadine hcl..... | 85 | dicyclomine hcl..... | 63 | EDARBYCLOR..... | 49 |
| | | didanosine..... | 36 | EDURANT..... | 35 |
| | | DIFICID..... | 10 | efavirenz..... | 35 |
| | | diflunisal..... | 2 | efavirenz-emtricitab-tenofovir | 36 |
| | | DIGITEK..... | 49 | efavirenz-lamivudine-tenofovir | 36 |
| | | DIGOX..... | 49 | | |

| | | | | | |
|---------------------------------|--------|---------------------------------|------------|----------------------------------|----|
| GATTEX..... | 63 | HUMIRA PEN-CD/UC/HS | | insulin aspart flexpen..... | 42 |
| GAVILYTE-C..... | 62 | STARTER | 78 | insulin aspart penfill | 42 |
| GAVILYTE-G | 62 | HUMIRA PEN-PS/UV/ADOL | | insulin aspart prot & aspart.... | 42 |
| GAVILYTE-N WITH FLAVOR | | HS START | 78 | INTELENCE | 35 |
| PACK | 62 | HUMIRA PEN-PSOR/UVEIT | | INTRALIPID..... | 61 |
| GAVRETO..... | 25 | STARTER | 78 | INTRAROSA | 69 |
| gemfibrozil | 51 | hydralazine hcl | 53 | INTRON A | 77 |
| generlac | 62 | hydrochlorothiazide..... | 51 | INTROVALE | 69 |
| GENGRAF | 77, 78 | hydrocodone-acetaminophen.... | 3 | INVEGA SUSTENNA..... | 32 |
| GENTAK | 83 | hydrocodone-ibuprofen | 3 | INVEGA TRINZA | 32 |
| gentamicin in saline..... | 5 | hydrocortisone | 57, 66, 81 | INVIRASE | 37 |
| gentamicin sulfate | 6, 83 | hydrocortisone ace-pramoxine | 58 | INVOKAMET | 40 |
| GENVOYA | 35 | hydrocortisone valerate | 57 | INVOKAMET XR | 40 |
| GIANVI..... | 69 | hydrocortisone-acetic acid..... | 85 | INVOKANA..... | 40 |
| GILENYA | 55 | hydromorphone hcl..... | 4 | IPOL | 79 |
| GILOTRIF..... | 25 | hydroxychloroquine sulfate.... | 29 | ipratropium bromide..... | 86 |
| glatiramer acetate | 55 | hydroxyurea..... | 23 | ipratropium-albuterol..... | 89 |
| glimepiride | 40 | hydroxyzine hcl | 38 | irbesartan | 45 |
| glipizide..... | 40 | hydroxyzine pamoate | 38 | irbesartan-hydrochlorothiazide | |
| glipizide er..... | 40 | I | | | 50 |
| glipizide-metformin hcl..... | 40 | ibandronate sodium | 81 | IRESSA | 26 |
| global alcohol prep ease | 58 | IBRANCE | 26 | ISENTRESS | 35 |
| GLUCAGEN HYPOKIT | 41 | IBU | 2 | ISENTRESS HD | 35 |
| glucagon emergency..... | 41 | ibuprofen | 2 | ISIBLOOM..... | 69 |
| glyburide..... | 40 | ICLUSIG | 26 | ISOLYTE-P IN D5W | 61 |
| glyburide micronized..... | 40 | IDHIFA | 23 | ISOLYTE-S | 59 |
| glyburide-metformin | 40 | ILEVRO | 83 | isoniazid..... | 22 |
| glycopyrrolate..... | 63 | imatinib mesylate | 26 | isosorbide dinitrate | 53 |
| granisetron hcl | 18 | IMBRUVICA | 26 | isosorbide mononitrate | 53 |
| griseofulvin microsize | 19 | imipenem-cilastatin | 10 | isosorbide mononitrate er | 53 |
| griseofulvin ultramicrosize.... | 19 | imipramine hcl..... | 17 | isotretinoin..... | 56 |
| guanfacine hcl | 45 | imipramine pamoate | 17 | isradipine | 47 |
| guanfacine hcl er | 54 | imiquimod | 58 | ISTURISA | 74 |
| guanidine hcl | 21 | IMOVAX RABIES | 79 | itraconazole..... | 19 |
| H | | IMVEXXY MAINTENANCE | | ivermectin | 29 |
| HAILEY 24 FE | 69 | PACK | 68 | IXIARO | 79 |
| halobetasol propionate..... | 57 | IMVEXXY STARTER PACK | | J | |
| haloperidol..... | 31 | | 68 | JAKAFI | 26 |
| haloperidol decanoate..... | 31 | INBRIJA..... | 30 | JANTOVEN | 44 |
| haloperidol lactate | 31 | INCASSIA..... | 73 | JANUMET | 40 |
| HAVRIX | 79 | INCRELEX | 67 | JANUMET XR..... | 40 |
| heparin sodium (porcine) | 44 | indapamide | 51 | JANUVIA..... | 40 |
| HEPATAMINE..... | 61 | indomethacin | 2 | JARDIANCE..... | 40 |
| HETLIOZ..... | 90 | indomethacin er | 2 | JASMIEL..... | 69 |
| HIBERIX..... | 79 | INFANRIX..... | 79 | JINTELI..... | 69 |
| HUMIRA..... | 78 | INLYTA | 26 | JUBLIA | 19 |
| HUMIRA PEDIATRIC | | INQOVI..... | 23 | JULEBER..... | 69 |
| CROHNS START | 78 | INREBIC | 26 | JULUCA..... | 36 |
| HUMIRA PEN | 78 | insulin asp prot & asp flexpen | 42 | JUNEL 1.5/30..... | 70 |
| | | insulin aspart..... | 42 | JUNEL 1/20..... | 70 |

| | | | | | |
|-----------------------------------|--------|----------------------------------|--------|----------------------------------|----|
| JUNEL FE 1.5/30..... | 70 | LARIN 1.5/30..... | 70 | lidocaine | 4 |
| JUNEL FE 1/20..... | 70 | LARIN 1/20..... | 70 | lidocaine hcl..... | 4 |
| JUNEL FE 24..... | 70 | LARIN FE 1.5/30..... | 70 | lidocaine hcl urethral/mucosal.. | 4 |
| K | | LARIN FE 1/20..... | 70 | lidocaine viscous hcl..... | 4 |
| KALETRA | 37 | LARISSIA | 70 | lidocaine-prilocaine | 4 |
| KALYDECO..... | 87, 88 | latanoprost | 85 | linezolid | 6 |
| KARIVA | 70 | LATUDA..... | 32 | LINZESS | 62 |
| KATERZIA..... | 47 | LEENA..... | 70 | liothyronine sodium..... | 74 |
| kcl in dextrose-nacl | 59 | leflunomide..... | 76 | lisinopril..... | 46 |
| kcl-lactated ringers-d5w | 59 | LENVIMA (10 MG DAILY | | lisinopril-hydrochlorothiazide | 50 |
| KELNOR 1/35..... | 70 | DOSE) | 26 | lithium..... | 39 |
| KELNOR 1/50..... | 70 | LENVIMA (12 MG DAILY | | lithium carbonate | 39 |
| KESIMPTA | 55 | DOSE) | 26 | lithium carbonate er | 39 |
| ketoconazole..... | 19 | LENVIMA (14 MG DAILY | | LIVALO | 52 |
| ketoprofen..... | 2 | DOSE) | 26 | LOKELMA..... | 62 |
| ketorolac tromethamine..... | 83 | LENVIMA (18 MG DAILY | | LONSURF..... | 23 |
| KINRIX..... | 79 | DOSE) | 26 | loperamide hcl | 63 |
| KISQALI (200 MG DOSE) ... | 26 | LENVIMA (20 MG DAILY | | lopinavir-ritonavir..... | 38 |
| KISQALI (400 MG DOSE) ... | 26 | DOSE) | 26 | lorazepam | 39 |
| KISQALI (600 MG DOSE) ... | 26 | LENVIMA (24 MG DAILY | | LORAZEPAM INTENSOL ... | 39 |
| KISQALI FEMARA (400 MG | | DOSE) | 27 | LORBRENA..... | 27 |
| DOSE) | 23 | LENVIMA (4 MG DAILY | | LORYNA | 70 |
| KISQALI FEMARA (600 MG | | DOSE) | 27 | losartan potassium | 45 |
| DOSE) | 23 | LENVIMA (8 MG DAILY | | losartan potassium-hctz | 50 |
| KISQALI FEMARA(200 MG | | DOSE) | 27 | loteprednol etabonate..... | 84 |
| DOSE) | 23 | LESSINA..... | 70 | lovastatin..... | 52 |
| KLOR-CON | 59 | letrozole..... | 24 | LOW-OGESTREL | 70 |
| KLOR-CON 10 | 59 | leucovorin calcium | 23 | loxapine succinate | 31 |
| KLOR-CON M10..... | 59 | LEUKERAN | 22 | LUMIGAN | 85 |
| KLOR-CON M15..... | 59 | leuprolide acetate..... | 74 | LUPRON DEPOT (1-MONTH) | |
| KLOR-CON M20..... | 59 | levabuterol hcl..... | 87 | | 74 |
| KORLYM..... | 41 | LEVEMIR | 42 | LUPRON DEPOT (3-MONTH) | |
| KOSELUGO | 26 | LEVEMIR FLEXTOUCH | 42 | | 75 |
| KURVELO..... | 70 | levetiracetam | 12 | LUPRON DEPOT (4-MONTH) | |
| KUVAN | 64 | levetiracetam er | 12 | | 75 |
| L | | levobunolol hcl..... | 84 | LUPRON DEPOT (6-MONTH) | |
| labetalol hcl | 47 | levocarnitine | 61 | | 75 |
| lactulose..... | 62 | levocetirizine dihydrochloride | 85 | LUTERA | 70 |
| lamivudine..... | 34, 36 | levofloxacin..... | 11, 83 | LYNPARZA..... | 23 |
| lamivudine-zidovudine..... | 36 | levofloxacin in d5w | 11 | LYSODREN..... | 22 |
| lamotrigine | 12 | LEVONEST | 70 | LYZA | 73 |
| lamotrigine er | 12 | levonorgest-eth estrad 91-day | 70 | M | |
| lamotrigine starter kit-blue | 12 | levonorgestrel-ethinyl estrad .. | 70 | magnesium sulfate | 59 |
| lamotrigine starter kit-green ... | 12 | levonorg-eth estrad triphasic .. | 70 | malathion | 58 |
| lamotrigine starter kit-orange . | 12 | LEVORA 0.15/30 (28) | 70 | maprotiline hcl..... | 15 |
| LAMPIT | 29 | LEVO-T..... | 74 | marlissa..... | 70 |
| lansoprazole..... | 64 | levothyroxine sodium..... | 74 | MARPLAN..... | 16 |
| LANTUS | 42 | LEVOXYL | 74 | MATULANE..... | 22 |
| LANTUS SOLOSTAR | 42 | LEXIVA | 38 | MATZIM LA..... | 48 |
| lapatinib ditosylate | 26 | LIALDA | 81 | MAVYRET | 34 |

| | | | | | |
|---------------------------------|----|---------------------------------|--------|-----------------------------------|--------|
| MAYZENT | 55 | MICROGESTIN 1.5/30..... | 71 | neomycin sulfate..... | 6 |
| meclizine hcl | 18 | MICROGESTIN 1/20..... | 71 | neomycin-bacitracin zn- | |
| medroxyprogesterone acetate. | 73 | MICROGESTIN FE 1.5/30.... | 71 | polymyx | 83 |
| mefloquine hcl..... | 29 | MICROGESTIN FE 1/20..... | 71 | neomycin-polymyxin-dexameth | |
| megestrol acetate | 73 | midodrine hcl..... | 45 | | 82 |
| MEKINIST..... | 27 | MIGERGOT | 20 | neomycin-polymyxin- | |
| MEKTOVI | 27 | miglitol | 40 | gramicidin..... | 82 |
| meloxicam | 2 | miglustat | 64 | neomycin-polymyxin-hc... | 82, 85 |
| memantine hcl | 14 | MILI | 71 | NEPHRAMINE..... | 61 |
| memantine hcl er | 14 | MINITRAN..... | 53 | NERLYNX..... | 27 |
| MENACTRA | 79 | minocycline hcl | 11 | NEUPRO | 30 |
| MENEST | 68 | minocycline hcl er | 11 | nevirapine | 36 |
| MENQUADFI..... | 79 | minoxidil | 53 | nevirapine er | 36 |
| MENVEO..... | 80 | mirtazapine | 15 | NEXAVAR..... | 27 |
| mercaptapurine..... | 78 | misoprostol | 63 | niacin er (antihyperlipidemic) | 52 |
| meropenem | 10 | M-M-R II..... | 80 | NIACOR..... | 52 |
| mesalamine..... | 81 | modafinil | 90 | nicardipine hcl | 47 |
| mesalamine er..... | 81 | moexipril hcl..... | 46 | NICOTROL..... | 5 |
| MESNEX | 23 | molindone hcl..... | 31 | nifedipine..... | 48 |
| metaproterenol sulfate | 87 | mometasone furoate | 57, 86 | nifedipine er..... | 47 |
| metaxalone | 90 | montelukast sodium..... | 86 | nifedipine er osmotic release.. | 47 |
| metformin hcl | 40 | morphine sulfate..... | 4 | NIKKI..... | 71 |
| metformin hcl er | 40 | morphine sulfate (concentrate). | 4 | nilutamide..... | 22 |
| methadone hcl | 3 | morphine sulfate er..... | 3 | nimodipine..... | 48 |
| methazolamide | 84 | MOVANTIK | 62 | NINLARO | 23 |
| methenamine hippurate | 6 | MOXEZA..... | 83 | nisoldipine er | 48 |
| methimazole | 75 | moxifloxacin hcl..... | 11, 83 | nitisinone | 64 |
| methocarbamol..... | 90 | moxifloxacin hcl in nacl..... | 11 | NITRO-BID..... | 53 |
| methotrexate | 78 | MULTAQ..... | 46 | NITRO-DUR | 53 |
| methotrexate sodium | 78 | mupirocin..... | 59 | nitrofurantoin..... | 7 |
| methotrexate sodium (pf) | 78 | mycophenolate mofetil..... | 78 | nitrofurantoin macrocrystal | 7 |
| methoxsalen rapid | 58 | mycophenolate sodium..... | 78 | nitrofurantoin monohyd macro. | 7 |
| methyl dopa..... | 45 | MYRBETRIQ | 65 | nitroglycerin | 53 |
| methyl dopa-hydrochlorothiazide | | N | | nizatidine | 63 |
| | 50 | nabumetone | 2 | NOCDURNA | 67 |
| methylphenidate hcl | 54 | nadolol..... | 47 | NORA-BE | 73 |
| methylphenidate hcl er | 54 | nafcillin sodium..... | 9 | norethindrone..... | 73 |
| methylprednisolone | 66 | naloxone hcl | 5 | norethindrone acetate..... | 73 |
| metoclopramide hcl | 63 | naltrexone hcl | 5 | norethindrone acet-ethinyl est | 71 |
| metolazone | 51 | NAMZARIC..... | 15 | norethindrone-eth estradiol.... | 71 |
| metoprolol succinate er | 47 | naproxen | 3 | norgestimate-eth estradiol | 71 |
| metoprolol tartrate | 47 | naproxen sodium | 3 | norgestim-eth estrad triphasic. | 71 |
| metoprolol-hydrochlorothiazide | | naratriptan hcl..... | 21 | NORMOSOL-M IN D5W | 59 |
| | 50 | NARCAN..... | 5 | NORTHERA | 45 |
| metronidazole | 7 | NATACYN | 83 | NORTREL 0.5/35 (28)..... | 71 |
| metronidazole in nacl | 7 | nateglinide | 40 | NORTREL 1/35 (21)..... | 71 |
| metyrosine | 50 | NATPARA | 81 | NORTREL 1/35 (28)..... | 71 |
| mexiletine hcl | 46 | NAYZILAM..... | 13 | NORTREL 7/7/7 | 71 |
| micafungin sodium..... | 19 | NECON 0.5/35 (28) | 71 | nortriptyline hcl | 17 |
| miconazole 3 | 19 | nefazodone hcl..... | 16 | NORVIR..... | 38 |

| | | | | | |
|---------------------------------|--------|------------------------------------|--------|---------------------------------|--------|
| NOVOLIN 70/30..... | 42 | oxandrolone | 67 | pimecrolimus | 57 |
| NOVOLIN 70/30 FLEXPEN | 42 | oxaprozin | 3 | pimozide | 31 |
| NOVOLIN N..... | 42 | oxazepam..... | 38 | PIMTREA..... | 71 |
| NOVOLIN N FLEXPEN | 42 | oxcarbazepine..... | 14 | pindolol..... | 47 |
| NOVOLIN R..... | 42 | oxybutynin chloride..... | 65 | pioglitazone hcl | 41 |
| NOVOLIN R FLEXPEN | 42 | oxybutynin chloride er..... | 65 | pioglitazone hcl-glimepiride.. | 41 |
| NOVOLOG | 43 | oxycodone hcl..... | 4 | pioglitazone hcl-metformin hcl | |
| NOVOLOG FLEXPEN..... | 43 | oxycodone hcl er | 3 | | 41 |
| NOVOLOG MIX 70/30 | 43 | oxycodone-acetaminophen..... | 4 | piperacillin sod-tazobactam so | 10 |
| NOVOLOG MIX 70/30 | | oxycodone-aspirin | 4 | PIQRAY (200 MG DAILY | |
| FLEXPEN | 43 | OZEMPIC (0.25 OR 0.5 | | DOSE) | 27 |
| NOVOLOG PENFILL | 43 | MG/DOSE)..... | 40 | PIQRAY (250 MG DAILY | |
| NOXAFIL | 19 | OZEMPIC (1 MG/DOSE)..... | 41 | DOSE) | 27 |
| NUBEQA | 22 | P | | PIQRAY (300 MG DAILY | |
| NUCALA | 89 | PACERONE..... | 46 | DOSE) | 27 |
| NUEDEXTA | 54 | paliperidone er..... | 33 | PIRMELLA 1/35 | 71 |
| NUPLAZID..... | 32 | pantoprazole sodium..... | 64 | piroxicam..... | 3 |
| NUTRILIPID | 61 | paricalcitol | 81 | PLASMA-LYTE 148 | 60 |
| NYAMYC | 19 | paromomycin sulfate | 6 | PLASMA-LYTE A | 60 |
| NYMALIZE..... | 48 | paroxetine hcl | 17 | PLENAMINE | 61 |
| nystatin | 19, 20 | paroxetine hcl er | 17 | podofilox..... | 58 |
| nystatin-triamcinolone..... | 58 | PASER..... | 22 | polymyxin b-trimethoprim | 82 |
| NYSTOP | 20 | PAXIL | 17 | POMALYST..... | 22 |
| O | | PAZEO | 83 | PORTIA-28 | 71 |
| OCELLA | 71 | PEDIARIX | 80 | posaconazole..... | 20 |
| OCTAGAM..... | 76 | PEDVAX HIB..... | 80 | potassium chloride..... | 60 |
| octreotide acetate..... | 75 | peg 3350-kcl-na bicarb-nacl... | 62 | potassium chloride crys er..... | 60 |
| ODEFSEY | 36 | peg-3350/electrolytes | 62 | potassium chloride er..... | 60 |
| ODOMZO | 27 | PEGASYS | 77 | potassium chloride in dextrose | |
| OFEV | 89 | PEMAZYRE | 27 | | 60 |
| ofloxacin..... | 83, 85 | penicillamine | 66 | potassium chloride in nacl..... | 60 |
| olanzapine..... | 32 | penicillin g pot in dextrose | 9 | potassium citrate er..... | 60 |
| olanzapine-fluoxetine hcl | 15 | penicillin g potassium..... | 9 | pramipexole dihydrochloride.. | 30 |
| olmesartan medoxomil | 45 | penicillin g sodium | 9 | prasugrel hcl | 45 |
| olmesartan medoxomil-hctz ... | 50 | penicillin v potassium..... | 9 | pravastatin sodium..... | 52 |
| olmesartan-amlodipine-hctz ... | 50 | pentamidine isethionate..... | 29 | prazosin hcl..... | 45 |
| olopatadine hcl | 83 | pentoxifylline er | 50 | prednisolone | 66 |
| omega-3-acid ethyl esters..... | 52 | perindopril erbumine | 46 | prednisolone acetate | 84 |
| omeprazole | 64 | permethrin | 58 | prednisolone sodium phosphate | |
| OMNITROPE..... | 67 | perphenazine..... | 31 | | 66, 84 |
| ondansetron | 18 | perphenazine-amitriptyline..... | 15 | prednisone..... | 66 |
| ondansetron hcl | 18 | PERSERIS..... | 33 | PREDNISONE INTENSOL... | 66 |
| OPSUMIT | 88 | phenelzine sulfate | 16 | preferred plus insulin syringe. | 43 |
| ORFADIN | 64 | phenobarbital | 12 | pregabalin | 54 |
| ORLISSA | 75 | phenytoin | 14 | PREMARIN | 68 |
| ORKAMBI..... | 88 | phenytoin sodium extended... | 14 | PREMASOL..... | 61 |
| ORSYTHIA..... | 71 | PHOSPHOLINE IODIDE..... | 84 | PREMPHASE..... | 71 |
| oseltamivir phosphate..... | 38 | PICATO..... | 58 | PREMPRO | 71 |
| OSPHENA | 73 | PIFELTRO | 36 | prenatal | 61 |
| oxacillin sodium | 9 | pilocarpine hcl | 55, 84 | PREVALITE | 52 |

| | |
|--------------------------------|--------|
| PREVIFEM | 71 |
| PREZCOBIX..... | 38 |
| PREZISTA | 38 |
| PRIFTIN..... | 21 |
| primaquine phosphate | 29 |
| primidone | 12 |
| PRIVIGEN | 76 |
| PROAIR HFA | 87 |
| PROAIR RESPICLICK | 87 |
| probenecid | 20 |
| PROCALAMINE..... | 61 |
| prochlorperazine..... | 18 |
| prochlorperazine maleate | 18 |
| PROCTO-MED HC | 57 |
| PROCTO-PAK..... | 57 |
| PROCTOSOL HC..... | 57 |
| PROCTOZONE-HC..... | 57 |
| progesterone micronized | 73 |
| PROGRAF | 78 |
| PROLASTIN-C..... | 64 |
| PROLIA | 82 |
| PROMACTA..... | 44 |
| promethazine hcl | 18 |
| propafenone hcl | 46 |
| propafenone hcl er..... | 46 |
| proparacaine hcl | 82 |
| propranolol hcl | 21, 47 |
| propranolol hcl er | 21, 47 |
| propranolol-hctz | 50 |
| propylthiouracil | 75 |
| PROQUAD..... | 80 |
| PROSOL..... | 61 |
| protriptyline hcl | 17 |
| PULMOZYME..... | 88 |
| PURIXAN | 23 |
| PYLERA | 63 |
| pyrazinamide | 22 |
| pyridostigmine bromide | 21 |
| pyrimethamine..... | 29 |

Q

| | |
|-------------------------------------|----|
| QBRELIS | 46 |
| QINLOCK..... | 27 |
| QUADRACEL | 80 |
| quetiapine fumarate | 33 |
| quetiapine fumarate er..... | 33 |
| quinapril hcl..... | 46 |
| quinapril-hydrochlorothiazide | 50 |
| quinidine sulfate | 46 |
| quinine sulfate | 29 |

R

| | |
|-------------------------------|----|
| RABAVERT | 80 |
| rabeprazole sodium..... | 64 |
| raloxifene hcl..... | 73 |
| ramipril | 46 |
| ranolazine er | 50 |
| rasagiline mesylate | 31 |
| RECLIPSEN..... | 72 |
| RECOMBIVAX HB..... | 80 |
| RECTIV..... | 53 |
| REGRANEX | 58 |
| RELENZA DISKHALER | 38 |
| RELI-ON INSULIN SYRINGE | 43 |
| repaglinide | 41 |
| REPATHA..... | 52 |
| REPATHA PUSHTRONEX | 52 |
| REPATHA SURECLICK | 52 |
| RESTASIS..... | 82 |
| RETACRIT | 44 |
| RETEVMO..... | 27 |
| REVLIMID | 22 |
| REXULTI..... | 33 |
| REYATAZ | 38 |
| RHOPRESSA..... | 85 |
| ribavirin | 34 |
| rifabutin | 21 |
| rifampin | 22 |
| riluzole..... | 54 |
| rimantadine hcl..... | 38 |
| RIOMET ER..... | 41 |
| risedronate sodium | 82 |
| RISPERDAL CONSTA | 33 |
| risperidone | 33 |
| ritonavir | 38 |
| rivastigmine..... | 15 |
| rivastigmine tartrate..... | 15 |
| rizatriptan benzoate | 21 |
| ROCKLATAN | 84 |
| ropinirole hcl | 30 |
| rosuvastatin calcium | 52 |
| ROTARIX | 80 |
| ROTATEQ | 80 |
| ROZLYTREK | 27 |
| RUBRACA..... | 27 |
| rukobia..... | 37 |
| RYBELSUS..... | 41 |
| RYDAPT | 27 |
| RYTARY..... | 31 |

S

| | |
|---|--------|
| SAMSCA..... | 60 |
| SANDIMMUNE..... | 78 |
| SANTYL | 58 |
| SAPHRIS..... | 33 |
| sapropterin dihydrochloride...64, 65 | |
| SAVELLA | 54 |
| SAVELLA TITRATION PACK | 54 |
| scopolamine..... | 18 |
| SECUADO | 33 |
| selegiline hcl..... | 31 |
| selenium sulfide..... | 57 |
| SELZENTRY | 37 |
| SEREVENT DISKUS | 87 |
| sertraline hcl | 17 |
| SETLAKIN..... | 72 |
| sevelamer carbonate | 62 |
| SHAROBEL | 73 |
| SHINGRIX | 80 |
| SIGNIFOR..... | 75 |
| sildenafil citrate | 88 |
| silodosin..... | 65 |
| silver sulfadiazine..... | 58 |
| SIMBRINZA | 85 |
| simvastatin..... | 52 |
| sirolimus | 78 |
| SIRTURO | 22 |
| SIVEXTRO | 7 |
| sodium chloride | 60 |
| sodium fluoride..... | 60 |
| sodium phenylbutyrate | 65 |
| sodium polystyrene sulfonate..... | 62 |
| sofosbuvir-velpatasvir | 34 |
| SOLQUA..... | 43 |
| SOLTAMOX..... | 23 |
| SOMATULINE DEPOT | 75 |
| SOMAVERT | 75 |
| sotalol hcl..... | 46 |
| sotalol hcl (af)..... | 46 |
| SPIRIVA HANDIHALER | 87 |
| SPIRIVA RESPIMAT | 87 |
| spironolactone..... | 51 |
| spironolactone-hctz..... | 50 |
| SPRINTEC 28 | 72 |
| SPRITAM..... | 12 |
| SPRYCEL..... | 27, 28 |
| SPS | 62 |
| SRONYX..... | 72 |

| | | | | | |
|-----------------------------------|--------|----------------------------------|--------|-----------------------------------|--------|
| SSD..... | 58 | TASIGNA | 28 | TOUJEO MAX SOLOSTAR | 43 |
| stavudine..... | 36, 37 | tazarotene..... | 56 | TOUJEO SOLOSTAR | 43 |
| STELARA | 76 | TAZORAC | 56 | TPN ELECTROLYTES | 61 |
| STIVARGA..... | 28 | TAZTIA XT | 48 | tramadol hcl | 4 |
| streptomycin sulfate | 6 | TAZVERIK..... | 28 | tramadol-acetaminophen | 4 |
| STRIBILD..... | 35 | TDVAX..... | 80 | trandolapril | 46 |
| SUBOXONE | 5 | TECFIDERA..... | 55 | trandolapril-verapamil hcl er .. | 50 |
| sucralfate | 63 | TEFLARO | 8 | tranexamic acid..... | 44 |
| sulfacetamide sodium..... | 83 | TEGSEDI | 65 | TRANSDERM-SCOP (1.5 MG) | |
| sulfacetamide sodium (acne).. | 11 | TEKTURNA HCT | 50 | | 18 |
| sulfacetamide-prednisolone.... | 82 | telmisartan | 45 | tranylcypromine sulfate | 16 |
| sulfadiazine..... | 11 | telmisartan-amlodipine..... | 50 | TRAVASOL..... | 61 |
| sulfamethoxazole-trimethoprim | | telmisartan-hctz | 50 | travoprost (bak free) | 85 |
| | 11 | temazepam..... | 90 | trazodone hcl | 17 |
| sulfasalazine | 81 | TENIVAC | 80 | TRECATOR..... | 22 |
| sulindac..... | 3 | tenofovir disoproxil fumarate. | 37 | TRELEGY ELLIPTA..... | 89 |
| sumatriptan | 21 | terazosin hcl..... | 45 | TRELSTAR MIXJECT | 75 |
| sumatriptan succinate | 21 | terbinafine hcl..... | 20 | TRESIBA | 43 |
| sumatriptan succinate refill | 21 | terbutaline sulfate | 87 | TRESIBA FLEXTOUCH..... | 43 |
| SUNOSI | 90 | terconazole..... | 20 | tretinoin..... | 29, 56 |
| SUPREP BOWEL PREP KIT | 60 | teriparatide (recombinant) | 82 | TREXALL..... | 78 |
| SUTENT..... | 28 | testosterone..... | 67 | triamcinolone acetonide...55, 57, | |
| SYEDA..... | 72 | testosterone cypionate | 67 | 58 | |
| SYMBICORT..... | 89 | testosterone enanthate..... | 67 | triamterene | 51 |
| SYMDEKO | 88 | tetrabenazine..... | 54 | triamterene-hctz | 50 |
| SYMFI..... | 37 | THALOMID..... | 23 | trientine hcl..... | 60 |
| SYMFI LO | 37 | theophylline er..... | 88 | TRI-ESTARYLLA..... | 72 |
| SYMJEPI..... | 87 | thioridazine hcl | 31 | trifluoperazine hcl..... | 31 |
| SYMLINPEN 120 | 41 | thiothixene | 31 | trifluridine..... | 35 |
| SYMLINPEN 60 | 41 | TIADYLT ER..... | 48 | trihexyphenidyl hcl..... | 30 |
| SYMPAZAN..... | 13 | tiagabine hcl | 13 | TRIKAFTA | 88 |
| SYMTUZA..... | 35 | TIBSOVO..... | 28 | TRI-LEGEST FE..... | 72 |
| SYNAREL | 75 | tigecycline | 7 | TRI-LO-ESTARYLLA | 72 |
| SYNJARDY..... | 41 | TIGLUTIK | 54 | TRI-LO-SPRINTEC..... | 72 |
| SYNJARDY XR | 41 | timolol maleate | 47, 84 | TRILYTE | 62 |
| SYNRIBO | 23 | tinidazole | 7 | trimethobenzamide hcl | 18 |
| SYNTHROID..... | 74 | TIROSINT..... | 74 | trimethoprim..... | 7 |
| T | | TIVICAY..... | 35 | TRI-MILI..... | 72 |
| TABLOID | 23 | TIVICAY PD | 35 | trimipramine maleate..... | 18 |
| TABRECTA..... | 28 | tizanidine hcl | 34 | TRINTELLIX..... | 17 |
| tacrolimus | 57, 78 | TOBI PODHALER | 88 | TRI-PREVIFEM..... | 72 |
| TAFINLAR | 28 | tobramycin..... | 83, 88 | TRI-SPRINTEC | 72 |
| TAGRISSE | 28 | tobramycin sulfate | 6 | TRIUMEQ..... | 37 |
| TAKHZYRO..... | 75 | tobramycin-dexamethasone.... | 82 | TRIVORA (28)..... | 72 |
| TALZENNA..... | 28 | tolterodine tartrate | 65 | TRI-VYLIBRA..... | 72 |
| tamoxifen citrate..... | 23 | tolterodine tartrate er | 65 | TRI-VYLIBRA LO | 72 |
| tamsulosin hcl..... | 65 | tolvaptan | 60 | TROPHAMINE..... | 61 |
| TARGRETIN | 29 | topiramate..... | 21 | trospium chloride..... | 65 |
| TARINA 24 FE..... | 72 | toremifene citrate..... | 23 | trospium chloride er..... | 65 |
| TARINA FE 1/20 EQ..... | 72 | torsemide | 51 | TRULICITY | 41 |

| | | | | | |
|-------------------------------|--------|-------------------------|--------|----------------------------|----|
| TRUMENBA | 80 | vigabatrin..... | 14 | XPOVIO (40 MG TWICE | |
| TRUVADA | 37 | VIGADRONE | 14 | WEEKLY)..... | 24 |
| TUKYSA..... | 28 | VIIBRYD | 17 | XPOVIO (60 MG ONCE | |
| TURALIO | 28 | VIIBRYD STARTER PACK | 17 | WEEKLY)..... | 24 |
| TWINRIX..... | 80 | VIMPAT..... | 14 | XPOVIO (60 MG TWICE | |
| TYBOST | 37 | VIRACEPT | 38 | WEEKLY)..... | 24 |
| TYKERB..... | 28 | VIREAD..... | 37 | XPOVIO (80 MG ONCE | |
| TYMLOS | 82 | VITRAKVI..... | 28 | WEEKLY)..... | 24 |
| TYPHIM VI..... | 80 | VIVITROL | 5 | XPOVIO (80 MG TWICE | |
| U | | VIZIMPRO..... | 28 | WEEKLY)..... | 24 |
| UNITHROID..... | 74 | voriconazole | 20 | XTANDI..... | 22 |
| UPTRAVI..... | 88 | VOSEVI | 34 | XULTOPHY..... | 41 |
| ursodiol..... | 63 | VOTRIENT | 28 | XYREM..... | 90 |
| V | | VRAYLAR..... | 33 | Y | |
| valacyclovir hcl | 35 | VYFEMLA..... | 72 | YF-VAX..... | 80 |
| VALCHLOR | 22 | VYLIBRA | 72 | YUVAFEM | 68 |
| valganciclovir hcl | 34 | VYNDAMAX | 65 | Z | |
| valproic acid | 12, 13 | W | | zafirlukast | 86 |
| valsartan | 45 | warfarin sodium..... | 44 | zaleplon..... | 90 |
| valsartan-hydrochlorothiazide | 51 | WELCHOL | 53 | ZARAH | 72 |
| VALTOCO 10 MG DOSE..... | 13 | X | | ZARXIO | 44 |
| VALTOCO 15 MG DOSE..... | 13 | XALKORI..... | 28 | ZEJULA | 29 |
| VALTOCO 20 MG DOSE..... | 13 | XARELTO | 44 | ZELBORAF | 29 |
| VALTOCO 5 MG DOSE..... | 14 | XARELTO STARTER PACK | | ZEMDRI..... | 6 |
| vancomycin hcl | 7 | | 44 | ZENPEP | 65 |
| VAQTA..... | 80 | XATMEP..... | 23 | ZERBAXA | 8 |
| VARIVAX | 80 | XCOPRI | 13 | zidovudine | 37 |
| VARIZIG | 80 | XCOPRI (250 MG DAILY | | ZIEXTENZO | 44 |
| VASCEPA..... | 52, 53 | DOSE)..... | 13 | zileuton er | 86 |
| VELIVET | 72 | XCOPRI (350 MG DAILY | | ziprasidone hcl..... | 33 |
| VELPHORO..... | 62 | DOSE)..... | 13 | ziprasidone mesylate | 33 |
| VEMLIDY | 34 | XELJANZ | 76 | ZIRGAN | 34 |
| VENCLEXTA | 28 | XELJANZ XR..... | 76 | ZOLINZA..... | 24 |
| VENCLEXTA STARTING | | XGEVA..... | 82 | zolpidem tartrate..... | 90 |
| PACK..... | 28 | XIFAXAN | 7 | zonisamide..... | 13 |
| venlafaxine hcl | 17 | XOFLUZA (40 MG DOSE)... | 38 | ZORTRESS | 79 |
| venlafaxine hcl er | 17 | XOFLUZA (80 MG DOSE)... | 38 | ZOVIA 1/35E (28) | 72 |
| verapamil hcl | 48 | XOLAIR..... | 76, 77 | ZYDELIG..... | 29 |
| verapamil hcl er..... | 48 | XOSPATA..... | 29 | ZYFLO | 86 |
| VERELAN | 48 | XPOVIO (100 MG ONCE | | ZYKADIA | 29 |
| VERSACLOZ | 34 | WEEKLY)..... | 24 | ZYPITAMAG..... | 52 |
| VERZENIO..... | 28 | XPOVIO (40 MG ONCE | | ZYPREXA RELPREVV | 33 |
| VICTOZA | 41 | WEEKLY)..... | 24 | ZYTIGA | 22 |
| VIENVA..... | 72 | | | | |

Insert Drug List and Index

Non-Discrimination Notice

HealthTeam Advantage complies with applicable federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, or sex. HealthTeam Advantage does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

HealthTeam Advantage:

Provides free aids and services to people with disabilities to communicate effectively with us, such as:

- ◆ Qualified sign language interpreters
- ◆ Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provides free language services to people whose primary language is not English, such as:

- ◆ Qualified interpreters
- ◆ Information written in other languages

If you need these services, contact your Healthcare Concierge at 833-324-3242 (TTY: 711) October 1-March 31, 8 a.m. to 8 p.m. ET, 7 days a week; April 1-September 30, 8 a.m. to 8 p.m. ET, Monday through Friday.

If you believe that HealthTeam Advantage has failed to provide these services or discriminated in another way based on race, color, national origin, age, disability, or sex, you can file a grievance with:

HealthTeam Advantage

Attn: Appeals and Grievances

7800 McCloud Road, Suite 100

Greensboro, NC 27409

833-324-3242, (TTY 711), or via fax at 800-845-4104.

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Appeals and Grievances Department is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/smartscreen/main.jsf>, by email OCRMail@hhs.gov, by phone 1-888-368-1019, TDD: 1-800-537-7697, or by mail U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201.

Get Help in Other Languages

If you need help or speak a non-English language, call 833-324-3242 TTY: 711, and you will be connected to an interpreter who will assist you at no cost.

HealthTeam Advantage, a product of Care N' Care Insurance Company of North Carolina, Inc., is a Medicare Advantage organization with a Medicare contract. Enrollment in HealthTeam Advantage depends on contract renewal.

YMULTI-PLAN_21_20_C

HealthTeam Advantage Diabetes & Heart Care Plan Contact Information

WEB ADDRESS

Visit HealthTeam Advantage Diabetes & Heart Care Plan at HealthTeamAdvantage.com

HEALTHCARE CONCIERGE

Current HealthTeam Advantage Diabetes & Heart Care Plan members call your Healthcare Concierge toll-free at 833-324-3242 for questions related to your HealthTeam Advantage Diabetes & Heart Care Plan Medicare Advantage Plan from October 1 - March 31, 8 a.m. to 8 p.m. ET, seven days a week, or April 1 - September 30, 8 a.m. to 8 p.m. ET, Monday through Friday.

SALES INFORMATION

Prospective members call toll-free 877-905-9216 for questions related to HealthTeam Advantage Diabetes & Heart Care Plan Medicare Advantage Plans from October 1 - March 31, 8 a.m. to 8 p.m. ET, seven days a week, or April 1 - September 30, 8 a.m. to 8 p.m. ET, Monday through Friday.

TTY USERS

TTY users call toll-free 711 for questions related to Medicare Advantage Plans.

PRESCRIPTION DRUG BENEFIT

Current HealthTeam Advantage Diabetes & Heart Care Plan members call toll-free 833-324-3242 for questions related to your HealthTeam Advantage Diabetes & Heart Care Plan Part D Prescription Drug Benefit. Prospective members call toll-free 877-905-9216 for questions related to the HealthTeam Advantage Diabetes & Heart Care Plan Part D Prescription Drug Benefit.

MEDICARE INFORMATION

For more information about Medicare, call Medicare at 1-800-Medicare (1-800-633-4227). TTY users should call 1-877-486-2048. You can call 24 hours a day, seven days a week or visit medicare.gov.

Formulary ID: 21526, Version Number: 6

This formulary was updated on 01/24/2021. HealthTeam Advantage Diabetes & Heart Care Plan, a product of Care N' Care Insurance Company of North Carolina, Inc., is a PPO and HMO Medicare Advantage plan with a Medicare contract. Enrollment in HealthTeam Advantage Diabetes & Heart Care Plan depends on contract renewal.

YMULTI-PLAN_21_03_C